<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	>

<channel>
	<title>Pharma Marketer</title>
	<atom:link href="http://pharma-marketer.brollyclient.ca/feed" rel="self" type="application/rss+xml" />
	<link>http://pharma-marketer.brollyclient.ca</link>
	<description>Conference-quality resources and connections without the travel</description>
	<pubDate>Thu, 11 Mar 2010 07:25:30 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.7.1</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>J&amp;J Pushed Risperdal for Elderly After U.S. Warning, Files Show</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/jj-pushed-risperdal-for-elderly-after-us-warning-files-show</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/jj-pushed-risperdal-for-elderly-after-us-warning-files-show#comments</comments>
		<pubDate>Thu, 11 Mar 2010 07:25:30 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[fierce-biotech]]></category>

		<category><![CDATA[motley-fool]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/jj-pushed-risperdal-for-elderly-after-us-warning-files-show</guid>
		<description><![CDATA[Bloomberg Wed, 03/10/10 - 9:16 am ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/jj-pushed-risperdal-for-elderly-after-us-warning-files-show/feed</wfw:commentRss>
		</item>
		<item>
		<title>Transgene Sells Option on Cancer Vaccine to Novartis</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/transgene-sells-option-on-cancer-vaccine-to-novartis</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/transgene-sells-option-on-cancer-vaccine-to-novartis#comments</comments>
		<pubDate>Thu, 11 Mar 2010 07:25:30 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[fierce-biotech]]></category>

		<category><![CDATA[motley-fool]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/transgene-sells-option-on-cancer-vaccine-to-novartis</guid>
		<description><![CDATA[Bloomberg Wed, 03/10/10 - 9:24 am ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/transgene-sells-option-on-cancer-vaccine-to-novartis/feed</wfw:commentRss>
		</item>
		<item>
		<title>FDA grants Cytokinetics treatment orphan status</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/fda-grants-cytokinetics-treatment-orphan-status</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/fda-grants-cytokinetics-treatment-orphan-status#comments</comments>
		<pubDate>Thu, 11 Mar 2010 07:25:29 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[fierce-biotech]]></category>

		<category><![CDATA[motley-fool]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/fda-grants-cytokinetics-treatment-orphan-status</guid>
		<description><![CDATA[Yahoo/AP Wed, 03/10/10 - 9:34 am ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/fda-grants-cytokinetics-treatment-orphan-status/feed</wfw:commentRss>
		</item>
		<item>
		<title>Biotech VCs, Big Pharma stepping outside the comfort zone</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/biotech-vcs-big-pharma-stepping-outside-the-comfort-zone</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/biotech-vcs-big-pharma-stepping-outside-the-comfort-zone#comments</comments>
		<pubDate>Thu, 11 Mar 2010 07:25:28 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[fierce-biotech]]></category>

		<category><![CDATA[motley-fool]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/biotech-vcs-big-pharma-stepping-outside-the-comfort-zone</guid>
		<description><![CDATA[Fierce Biotech Wed, 03/10/10 - 10:02 am ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/biotech-vcs-big-pharma-stepping-outside-the-comfort-zone/feed</wfw:commentRss>
		</item>
		<item>
		<title>5-Star Stocks Poised to Pop: Teva Pharmaceutical</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/5-star-stocks-poised-to-pop-teva-pharmaceutical</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/5-star-stocks-poised-to-pop-teva-pharmaceutical#comments</comments>
		<pubDate>Thu, 11 Mar 2010 07:25:25 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[motley-fool]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/5-star-stocks-poised-to-pop-teva-pharmaceutical</guid>
		<description><![CDATA[Motley Fool Wed, 03/10/10 - 10:12 am ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/5-star-stocks-poised-to-pop-teva-pharmaceutical/feed</wfw:commentRss>
		</item>
		<item>
		<title>Cervarix – Maintenant offert aux Canadiennes</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/cervarix-%e2%80%93-maintenant-offert-aux-canadiennes</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/cervarix-%e2%80%93-maintenant-offert-aux-canadiennes#comments</comments>
		<pubDate>Wed, 10 Mar 2010 23:00:47 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[bivalent]]></category>

		<category><![CDATA[double-page]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[north america]]></category>

		<category><![CDATA[oncogenic-human]]></category>

		<category><![CDATA[prevention]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[the-largest]]></category>

		<category><![CDATA[the-prevention]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/cervarix-%e2%80%93-maintenant-offert-aux-canadiennes</guid>
		<description><![CDATA[ Cervarix. Maintenant offert aux Canadiennes. Brand name: Cervarix Generic name/category: Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant Company: GlaxoSmithKline Country/Market: Canada, North America Indication(s)/use: the prevention of cervical cancer and cervical intraepithelial neoplasia caused by oncogenic human papillomavirus (HPV) types 16 and 18 Target: Healthcare Professionals (HCP) Tagline: n/a Medium: Print ad Size/duration: Double-page spread Publication/Aired: March 2010 To see all of this brand&#8217;s ads on AdPharm, click here Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/cervarix-%e2%80%93-maintenant-offert-aux-canadiennes/feed</wfw:commentRss>
		</item>
		<item>
		<title>Help prevent cervical cancer TV spots</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/help-prevent-cervical-cancer-tv-spots</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/help-prevent-cervical-cancer-tv-spots#comments</comments>
		<pubDate>Wed, 10 Mar 2010 22:50:59 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[bivalent]]></category>

		<category><![CDATA[cervarix]]></category>

		<category><![CDATA[double-page]]></category>

		<category><![CDATA[glaxosmithkline]]></category>

		<category><![CDATA[gsk]]></category>

		<category><![CDATA[north america]]></category>

		<category><![CDATA[not-too]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[tv commercials]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/help-prevent-cervical-cancer-tv-spots</guid>
		<description><![CDATA[ Here are 3 cervical cancer awareness TV commercials from GlaxoSmithKline. Night out Front porch Perfume Cervarix, GSK&#8217;s vaccine for cervical cancer was launched not too long ago in the US and Canada Click here to see the healthcare professional print ads]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/help-prevent-cervical-cancer-tv-spots/feed</wfw:commentRss>
		</item>
		<item>
		<title>InterMuneâs Lung Drug Gets Backing From FDA Panel</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/intermunea%c2%80%c2%99s-lung-drug-gets-backing-from-fda-panel</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/intermunea%c2%80%c2%99s-lung-drug-gets-backing-from-fda-panel#comments</comments>
		<pubDate>Wed, 10 Mar 2010 22:41:26 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[cnbc]]></category>

		<category><![CDATA[online]]></category>

		<category><![CDATA[wsj]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/intermunea%c2%80%c2%99s-lung-drug-gets-backing-from-fda-panel</guid>
		<description><![CDATA[WSJ Online Wed, 03/10/10 - 10:46 am ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/intermunea%c2%80%c2%99s-lung-drug-gets-backing-from-fda-panel/feed</wfw:commentRss>
		</item>
		<item>
		<title>A Tale Of Two Sectors</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/a-tale-of-two-sectors</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/a-tale-of-two-sectors#comments</comments>
		<pubDate>Wed, 10 Mar 2010 22:41:25 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[cnbc]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/a-tale-of-two-sectors</guid>
		<description><![CDATA[CNBC Wed, 03/10/10 - 11:08 am ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/a-tale-of-two-sectors/feed</wfw:commentRss>
		</item>
		<item>
		<title>Biotechs Jump on Facet, Intermune Deal</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/biotechs-jump-on-facet-intermune-deal</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/biotechs-jump-on-facet-intermune-deal#comments</comments>
		<pubDate>Wed, 10 Mar 2010 22:41:25 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/biotechs-jump-on-facet-intermune-deal</guid>
		<description><![CDATA[Barron&#039;s Wed, 03/10/10 - 11:17 am ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/biotechs-jump-on-facet-intermune-deal/feed</wfw:commentRss>
		</item>
		<item>
		<title>3 Biotech Stocks On The Move</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/3-biotech-stocks-on-the-move</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/3-biotech-stocks-on-the-move#comments</comments>
		<pubDate>Wed, 10 Mar 2010 22:41:24 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/3-biotech-stocks-on-the-move</guid>
		<description><![CDATA[Investopedia Wed, 03/10/10 - 11:18 am ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/3-biotech-stocks-on-the-move/feed</wfw:commentRss>
		</item>
		<item>
		<title>Aleve – If you could take fewer pills…</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/aleve-%e2%80%93-if-you-could-take-fewer-pills%e2%80%a6</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/aleve-%e2%80%93-if-you-could-take-fewer-pills%e2%80%a6#comments</comments>
		<pubDate>Wed, 10 Mar 2010 22:00:43 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[arthritis]]></category>

		<category><![CDATA[consumers]]></category>

		<category><![CDATA[DTC]]></category>

		<category><![CDATA[fewer-pills]]></category>

		<category><![CDATA[non-steroidal]]></category>

		<category><![CDATA[north america]]></category>

		<category><![CDATA[take-fewer]]></category>

		<category><![CDATA[the-largest]]></category>

		<category><![CDATA[usa]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/aleve-%e2%80%93-if-you-could-take-fewer-pills%e2%80%a6</guid>
		<description><![CDATA[ If you could take fewer pills, why wouldn&#8217;t you? Brand name: Aleve Generic name/category: Naproxen Sodium, Non-steroidal anti-inflammatory drugs (NSAID), Carboxylic acids Company: Bayer Healthcare Country/Market: USA, North America Indication(s)/use: Arthritis, moderate to severe pain, fever, inflammation and stiffness Target: Consumers (DTC) Tagline: Fewer pills. All-day relief]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/aleve-%e2%80%93-if-you-could-take-fewer-pills%e2%80%a6/feed</wfw:commentRss>
		</item>
		<item>
		<title>Iberogast – for IBS</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/iberogast-%e2%80%93-for-ibs</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/iberogast-%e2%80%93-for-ibs#comments</comments>
		<pubDate>Wed, 10 Mar 2010 21:00:40 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[consumers]]></category>

		<category><![CDATA[drazliwego]]></category>

		<category><![CDATA[flatulence]]></category>

		<category><![CDATA[heartburn]]></category>

		<category><![CDATA[irritable]]></category>

		<category><![CDATA[steigerwald]]></category>

		<category><![CDATA[usa]]></category>

		<category><![CDATA[zespolu-jelita]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/iberogast-%e2%80%93-for-ibs</guid>
		<description><![CDATA[ Iberogast Bol Zoladka &#8211; Wzdecia &#8211; Zgaga Skuteczny w leczeniu czynnosciowych zaburzen motoryki przewodu pokarmowego, w tym objawow Zespolu Jelita Drazliwego Iberogast Stomach ache &#8211; Flatulence &#8211; Heartburn Effective in the treatment of functional gastrointestinal motility disorders, including symptoms Irritable bowel syndrome Brand name: Iberogast Generic name/category: STW 5, is a prokinetic liquid formulation Company: Steigerwald Country/Market: Poland, Europe Indication(s)/use: Irritable Bowel Syndrome (IBS) and dyspepsia Target: Healthcare Professionals (HCP) Tagline: n/a Medium: Print ad Size/duration: One third of page Publication/Aired: June 2009 Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/iberogast-%e2%80%93-for-ibs/feed</wfw:commentRss>
		</item>
		<item>
		<title>PhRMA Recommended guidelines for drug Internet Marketing: Who speaks for patients ?</title>
		<link>http://pharma-marketer.brollyclient.ca/dtc/phrma-recommended-guidelines-for-drug-internet-marketing-who-speaks-for-patients</link>
		<comments>http://pharma-marketer.brollyclient.ca/dtc/phrma-recommended-guidelines-for-drug-internet-marketing-who-speaks-for-patients#comments</comments>
		<pubDate>Wed, 10 Mar 2010 20:50:38 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[DTC]]></category>

		<category><![CDATA[among-the-most]]></category>

		<category><![CDATA[drug]]></category>

		<category><![CDATA[drug-industry]]></category>

		<category><![CDATA[facebook]]></category>

		<category><![CDATA[internet]]></category>

		<category><![CDATA[pharma-on-their]]></category>

		<category><![CDATA[recommendation]]></category>

		<category><![CDATA[social]]></category>

		<category><![CDATA[trust-the-drug]]></category>

		<category><![CDATA[wants-the-fda]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/phrma-recommended-guidelines-for-drug-internet-marketing-who-speaks-for-patients</guid>
		<description><![CDATA[J&#038;J asked that companies not be held responsible for user comments they do not control. This is needed and should be accepted practice. There is no way that ANY drug company can control ALL user comments via any media. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/dtc/phrma-recommended-guidelines-for-drug-internet-marketing-who-speaks-for-patients/feed</wfw:commentRss>
		</item>
		<item>
		<title>Cymbalta – web banner</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/cymbalta-%e2%80%93-web-banner</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/cymbalta-%e2%80%93-web-banner#comments</comments>
		<pubDate>Wed, 10 Mar 2010 20:00:35 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[consumers]]></category>

		<category><![CDATA[DTC]]></category>

		<category><![CDATA[heartburn]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[north america]]></category>

		<category><![CDATA[snri]]></category>

		<category><![CDATA[steigerwald]]></category>

		<category><![CDATA[usa]]></category>

		<category><![CDATA[zespolu-jelita]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/cymbalta-%e2%80%93-web-banner</guid>
		<description><![CDATA[ Brand name: Cymbalta Generic name/category: Duloxetine, Serotonin-norepinephrine reuptake inhibitors (SNRI) Company: Lilly Country/Market: USA, North America Indication(s)/use: management of diabetic nerve pain Target: Consumers (DTC) Tagline: n/a Medium: web banner Size/duration: 300X250 Publication/Aired: October 2009 To see all of this brand&#8217;s ads on AdPharm, click here Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/cymbalta-%e2%80%93-web-banner/feed</wfw:commentRss>
		</item>
		<item>
		<title>9 Simple Steps to Getting Started in Social Media</title>
		<link>http://pharma-marketer.brollyclient.ca/internet-marketing/9-simple-steps-to-getting-started-in-social-media</link>
		<comments>http://pharma-marketer.brollyclient.ca/internet-marketing/9-simple-steps-to-getting-started-in-social-media#comments</comments>
		<pubDate>Wed, 10 Mar 2010 19:53:39 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Web Marketing]]></category>

		<category><![CDATA[facebook]]></category>

		<category><![CDATA[green]]></category>

		<category><![CDATA[mini white paper]]></category>

		<category><![CDATA[online]]></category>

		<category><![CDATA[opinion]]></category>

		<category><![CDATA[pharma]]></category>

		<category><![CDATA[powerpoint]]></category>

		<category><![CDATA[search-engine]]></category>

		<category><![CDATA[time]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/9-simple-steps-to-getting-started-in-social-media</guid>
		<description><![CDATA[ It&#8217;s clear that more and more companies are getting the green light from their leadership teams to get started in social media. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/internet-marketing/9-simple-steps-to-getting-started-in-social-media/feed</wfw:commentRss>
		</item>
		<item>
		<title>Vaccines in the Court</title>
		<link>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/vaccines-in-the-court</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/vaccines-in-the-court#comments</comments>
		<pubDate>Wed, 10 Mar 2010 18:43:36 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[In the Pipeline]]></category>

		<category><![CDATA[case-involves]]></category>

		<category><![CDATA[court]]></category>

		<category><![CDATA[court-decisions]]></category>

		<category><![CDATA[followup-law]]></category>

		<category><![CDATA[from-liability]]></category>

		<category><![CDATA[georgia]]></category>

		<category><![CDATA[georgia-supreme]]></category>

		<category><![CDATA[intent]]></category>

		<category><![CDATA[lower-court]]></category>

		<category><![CDATA[recently-held]]></category>

		<category><![CDATA[state-court]]></category>

		<category><![CDATA[supreme]]></category>

		<category><![CDATA[supreme-court]]></category>

		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/vaccines-in-the-court</guid>
		<description><![CDATA[ The Supreme Court has agreed to hear a vaccine-liability case, in an attempt to untangle conflicting lower court rulings. This all turns on the 1986 act that shields manufacturers from liability suits and a followup law that establishes a separate compensation system for injuries. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/vaccines-in-the-court/feed</wfw:commentRss>
		</item>
		<item>
		<title>Amylin, Lilly gear up for big FDA ruling</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/amylin-lilly-gear-up-for-big-fda-ruling</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/amylin-lilly-gear-up-for-big-fda-ruling#comments</comments>
		<pubDate>Wed, 10 Mar 2010 18:01:53 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[alkermes]]></category>

		<category><![CDATA[amylin pharmaceuticals]]></category>

		<category><![CDATA[bestselling]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[companies]]></category>

		<category><![CDATA[delay-the-drug]]></category>

		<category><![CDATA[eli lilly]]></category>

		<category><![CDATA[percent-royalty]]></category>

		<category><![CDATA[sales]]></category>

		<category><![CDATA[street]]></category>

		<category><![CDATA[street-journal]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/amylin-lilly-gear-up-for-big-fda-ruling</guid>
		<description><![CDATA[ Eli]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/amylin-lilly-gear-up-for-big-fda-ruling/feed</wfw:commentRss>
		</item>
		<item>
		<title>Enbrel – clearer skin</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/enbrel-%e2%80%93-clearer-skin</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/enbrel-%e2%80%93-clearer-skin#comments</comments>
		<pubDate>Wed, 10 Mar 2010 18:00:21 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[amgen]]></category>

		<category><![CDATA[clearer-skin]]></category>

		<category><![CDATA[consumers]]></category>

		<category><![CDATA[double-page]]></category>

		<category><![CDATA[enbrel]]></category>

		<category><![CDATA[heartburn]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[the-largest]]></category>

		<category><![CDATA[usa]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/enbrel-%e2%80%93-clearer-skin</guid>
		<description><![CDATA[ Clearer skin in 3 months Brand name: Enbrel Generic name/category: Etanercept Company: Wyeth and Amgen Country/Market: USA, North America Indication(s)/use: chronic moderate to severe plaque psoriasis Target: Consumers (DTC) Tagline: n/a Medium: Print ad Size/duration: Double-page spread Publication/Aired: February 2010 To see all of this brand&#8217;s ads on AdPharm, click here Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/enbrel-%e2%80%93-clearer-skin/feed</wfw:commentRss>
		</item>
		<item>
		<title>Cytokinetics gets orphan drug status for ALS drug</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/cytokinetics-gets-orphan-drug-status-for-als-drug</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/cytokinetics-gets-orphan-drug-status-for-als-drug#comments</comments>
		<pubDate>Wed, 10 Mar 2010 17:13:20 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[als]]></category>

		<category><![CDATA[amylin pharmaceuticals]]></category>

		<category><![CDATA[announced-today]]></category>

		<category><![CDATA[ck-2017357]]></category>

		<category><![CDATA[cytokinetics]]></category>

		<category><![CDATA[disease]]></category>

		<category><![CDATA[eli lilly]]></category>

		<category><![CDATA[granted-orphan-drug]]></category>

		<category><![CDATA[lateral-sclerosis]]></category>

		<category><![CDATA[orphan drug status]]></category>

		<category><![CDATA[phase]]></category>

		<category><![CDATA[sales]]></category>

		<category><![CDATA[street]]></category>

		<category><![CDATA[street-journal]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/cytokinetics-gets-orphan-drug-status-for-als-drug</guid>
		<description><![CDATA[ Cytokinetics announced today that its]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/cytokinetics-gets-orphan-drug-status-for-als-drug/feed</wfw:commentRss>
		</item>
		<item>
		<title>Good health has a lot of benefits including more sex but are Americans interested ?</title>
		<link>http://pharma-marketer.brollyclient.ca/dtc/good-health-has-a-lot-of-benefits-including-more-sex-but-are-americans-interested</link>
		<comments>http://pharma-marketer.brollyclient.ca/dtc/good-health-has-a-lot-of-benefits-including-more-sex-but-are-americans-interested#comments</comments>
		<pubDate>Wed, 10 Mar 2010 17:07:00 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[DTC]]></category>

		<category><![CDATA[change-consumer]]></category>

		<category><![CDATA[condition]]></category>

		<category><![CDATA[diet]]></category>

		<category><![CDATA[health]]></category>

		<category><![CDATA[health-recently]]></category>

		<category><![CDATA[major-overhaul]]></category>

		<category><![CDATA[marketing]]></category>

		<category><![CDATA[probably-needed]]></category>

		<category><![CDATA[time]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/good-health-has-a-lot-of-benefits-including-more-sex-but-are-americans-interested</guid>
		<description><![CDATA["If you are a man diagnosed with diabetes or high blood pressure and I tell you that you need to lose weight and take medication, and I can say the benefit is five extra years of sex life, you might be more inclined to do what I tell you," the author of a study on sex and health recently stated. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/dtc/good-health-has-a-lot-of-benefits-including-more-sex-but-are-americans-interested/feed</wfw:commentRss>
		</item>
		<item>
		<title>Ligue-cancer.net – mime tv commercial</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ligue-cancernet-%e2%80%93-mime-tv-commercial</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ligue-cancernet-%e2%80%93-mime-tv-commercial#comments</comments>
		<pubDate>Wed, 10 Mar 2010 17:00:31 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[consumers]]></category>

		<category><![CDATA[disease-awareness]]></category>

		<category><![CDATA[DTC]]></category>

		<category><![CDATA[europe]]></category>

		<category><![CDATA[france]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[ligue-contre]]></category>

		<category><![CDATA[online-pharmaceutical]]></category>

		<category><![CDATA[public]]></category>

		<category><![CDATA[the-largest]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/ligue-cancernet-%e2%80%93-mime-tv-commercial</guid>
		<description><![CDATA[ Brand name: La ligue contre le cancer Generic name/category: Public service Company: La ligue contre le cancer Country/Market: France, Europe Indication(s)/use: cancer, disease awareness Target: Consumers (DTC) Tagline: Pour la vie Medium: TV commercial Size/duration: 45 seconds Publication/Aired: 2009 To see all of this brand&#8217;s ads on AdPharm, click here Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ligue-cancernet-%e2%80%93-mime-tv-commercial/feed</wfw:commentRss>
		</item>
		<item>
		<title>Ligue-cancer.net – plus forts ensemble 2</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ligue-cancernet-%e2%80%93-plus-forts-ensemble-2</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ligue-cancernet-%e2%80%93-plus-forts-ensemble-2#comments</comments>
		<pubDate>Wed, 10 Mar 2010 16:00:38 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[consumers]]></category>

		<category><![CDATA[donateurs]]></category>

		<category><![CDATA[DTC]]></category>

		<category><![CDATA[est-plus]]></category>

		<category><![CDATA[france]]></category>

		<category><![CDATA[ligue-contre]]></category>

		<category><![CDATA[online-pharmaceutical]]></category>

		<category><![CDATA[plus-forts]]></category>

		<category><![CDATA[public]]></category>

		<category><![CDATA[the-largest]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/ligue-cancernet-%e2%80%93-plus-forts-ensemble-2</guid>
		<description><![CDATA[ Chercheurs Bénévoles Donateurs Malades Face au cancer, on est plus forts ensemble. Brand name: La ligue contre le cancer Generic name/category: Public service Company: La ligue contre le cancer Country/Market: France, Europe Indication(s)/use: cancer, disease awareness Target: Consumers (DTC) Tagline: Pour la vie Medium: Print ad Size/duration: Single-page Publication/Aired: September 2009 To see all of this brand&#8217;s ads on AdPharm, click here Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ligue-cancernet-%e2%80%93-plus-forts-ensemble-2/feed</wfw:commentRss>
		</item>
		<item>
		<title>Ligue-cancer.net – plus forts ensemble 1</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ligue-cancernet-%e2%80%93-plus-forts-ensemble-1</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ligue-cancernet-%e2%80%93-plus-forts-ensemble-1#comments</comments>
		<pubDate>Wed, 10 Mar 2010 16:00:30 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[consumers]]></category>

		<category><![CDATA[donateurs]]></category>

		<category><![CDATA[DTC]]></category>

		<category><![CDATA[france]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[the-largest]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/ligue-cancernet-%e2%80%93-plus-forts-ensemble-1</guid>
		<description><![CDATA[ Chercheurs Bénévoles Donateurs Malades Face au cancer, on est plus forts ensemble. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ligue-cancernet-%e2%80%93-plus-forts-ensemble-1/feed</wfw:commentRss>
		</item>
		<item>
		<title>Neuropharm mulls voluntary liquidation as it waits for deal</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/neuropharm-mulls-voluntary-liquidation-as-it-waits-for-deal</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/neuropharm-mulls-voluntary-liquidation-as-it-waits-for-deal#comments</comments>
		<pubDate>Wed, 10 Mar 2010 15:52:19 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[announced-today]]></category>

		<category><![CDATA[beating-early]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[ck-2017357]]></category>

		<category><![CDATA[disease]]></category>

		<category><![CDATA[due-diligence]]></category>

		<category><![CDATA[eli lilly]]></category>

		<category><![CDATA[lateral-sclerosis]]></category>

		<category><![CDATA[orphan drug status]]></category>

		<category><![CDATA[possibility]]></category>

		<category><![CDATA[spike-on-fresh]]></category>

		<category><![CDATA[tank-on-phase]]></category>

		<category><![CDATA[the-developer]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/neuropharm-mulls-voluntary-liquidation-as-it-waits-for-deal</guid>
		<description><![CDATA[ Shares of U.K.'s Neuropharm shot up 33 percent this morning when the developer announced that its]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/neuropharm-mulls-voluntary-liquidation-as-it-waits-for-deal/feed</wfw:commentRss>
		</item>
		<item>
		<title>EKR names interim president, CEO</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/ekr-names-interim-president-ceo</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/ekr-names-interim-president-ceo#comments</comments>
		<pubDate>Wed, 10 Mar 2010 15:46:04 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[board-at-kinex]]></category>

		<category><![CDATA[china-yongxin]]></category>

		<category><![CDATA[chutes and ladders]]></category>

		<category><![CDATA[disease]]></category>

		<category><![CDATA[from-the-board]]></category>

		<category><![CDATA[human-genome]]></category>

		<category><![CDATA[jingang-wang]]></category>

		<category><![CDATA[lateral-sclerosis]]></category>

		<category><![CDATA[phillip-frost]]></category>

		<category><![CDATA[robert-shepard]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/ekr-names-interim-president-ceo</guid>
		<description><![CDATA[ > EKR Therapeutics has announced that its executive chairman John Bailye has been appointed interim president and CEO replacing Howard Weisman , who is no longer with the company. Weisman will also no longer serve on EKR's board of directors. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/ekr-names-interim-president-ceo/feed</wfw:commentRss>
		</item>
		<item>
		<title>How Not to Do It: Liquid Oxygen Cylinders</title>
		<link>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/how-not-to-do-it-liquid-oxygen-cylinders</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/how-not-to-do-it-liquid-oxygen-cylinders#comments</comments>
		<pubDate>Wed, 10 Mar 2010 15:40:33 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[In the Pipeline]]></category>

		<category><![CDATA[accident]]></category>

		<category><![CDATA[airgas]]></category>

		<category><![CDATA[cylinder-kings]]></category>

		<category><![CDATA[how not to do it]]></category>

		<category><![CDATA[liquid-nitrogen]]></category>

		<category><![CDATA[photo]]></category>

		<category><![CDATA[plugged-it-shut]]></category>

		<category><![CDATA[pressure]]></category>

		<category><![CDATA[truck]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/how-not-to-do-it-liquid-oxygen-cylinders</guid>
		<description><![CDATA[ We haven't had a How Not to Do It around here in a while, so here's a companion piece to the famous Sealed-Up Liquid Nitrogen Tank . This incident happened (as far as I can tell) about ten years ago]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/how-not-to-do-it-liquid-oxygen-cylinders/feed</wfw:commentRss>
		</item>
		<item>
		<title>Ligue-cancer.net – Rejoignez l’équipe de France contre le cancer</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ligue-cancernet-%e2%80%93-rejoignez-l%e2%80%99equipe-de-france-contre-le-cancer</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ligue-cancernet-%e2%80%93-rejoignez-l%e2%80%99equipe-de-france-contre-le-cancer#comments</comments>
		<pubDate>Wed, 10 Mar 2010 15:00:27 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[consumers]]></category>

		<category><![CDATA[disease-awareness]]></category>

		<category><![CDATA[france]]></category>

		<category><![CDATA[half-page]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[public]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/ligue-cancernet-%e2%80%93-rejoignez-l%e2%80%99equipe-de-france-contre-le-cancer</guid>
		<description><![CDATA[ Rejoignez l&#8217;équipe de France contre le cancer. Brand name: La ligue contre le cancer Generic name/category: Public service Company: La ligue contre le cancer Country/Market: France, Europe Indication(s)/use: cancer, disease awareness Target: Consumers (DTC) Tagline: Pour la vie Medium: Print ad Size/duration: Half-page Publication/Aired: March 2010 To see all of this brand&#8217;s ads on AdPharm, click here Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ligue-cancernet-%e2%80%93-rejoignez-l%e2%80%99equipe-de-france-contre-le-cancer/feed</wfw:commentRss>
		</item>
		<item>
		<title>Cymbalta – Fibromyalgia. It’s what I have. Not who I am.</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/cymbalta-%e2%80%93-fibromyalgia-it%e2%80%99s-what-i-have-not-who-i-am</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/cymbalta-%e2%80%93-fibromyalgia-it%e2%80%99s-what-i-have-not-who-i-am#comments</comments>
		<pubDate>Wed, 10 Mar 2010 13:43:24 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[consumers]]></category>

		<category><![CDATA[DTC]]></category>

		<category><![CDATA[duloxetine]]></category>

		<category><![CDATA[fibromyalgia]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[north america]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[the-largest]]></category>

		<category><![CDATA[usa]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/cymbalta-%e2%80%93-fibromyalgia-it%e2%80%99s-what-i-have-not-who-i-am</guid>
		<description><![CDATA[ Fibromyalgia. It&#8217;s what I have. Not who I am]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/cymbalta-%e2%80%93-fibromyalgia-it%e2%80%99s-what-i-have-not-who-i-am/feed</wfw:commentRss>
		</item>
		<item>
		<title>Novartis offers $955M deal to snare Transgene drug option</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/novartis-offers-955m-deal-to-snare-transgene-drug-option</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/novartis-offers-955m-deal-to-snare-transgene-drug-option#comments</comments>
		<pubDate>Wed, 10 Mar 2010 11:09:43 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[after-enrolling]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[chutes and ladders]]></category>

		<category><![CDATA[disease]]></category>

		<category><![CDATA[french]]></category>

		<category><![CDATA[funding-remains]]></category>

		<category><![CDATA[technology]]></category>

		<category><![CDATA[transgene]]></category>

		<category><![CDATA[upcoming]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/novartis-offers-955m-deal-to-snare-transgene-drug-option</guid>
		<description><![CDATA[ Novartis has put up $10 million and promised up to &#8364;700 million]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/novartis-offers-955m-deal-to-snare-transgene-drug-option/feed</wfw:commentRss>
		</item>
		<item>
		<title>In 9-3 vote, expert panel backs InterMune&#8217;s pirfenidone</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/in-9-3-vote-expert-panel-backs-intermunes-pirfenidone</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/in-9-3-vote-expert-panel-backs-intermunes-pirfenidone#comments</comments>
		<pubDate>Wed, 10 Mar 2010 03:56:36 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[after-enrolling]]></category>

		<category><![CDATA[data]]></category>

		<category><![CDATA[french]]></category>

		<category><![CDATA[inter]]></category>

		<category><![CDATA[japan]]></category>

		<category><![CDATA[panel]]></category>

		<category><![CDATA[pirfenidone]]></category>

		<category><![CDATA[technology]]></category>

		<category><![CDATA[transgene]]></category>

		<category><![CDATA[upcoming]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/in-9-3-vote-expert-panel-backs-intermunes-pirfenidone</guid>
		<description><![CDATA[ An FDA expert panel voted 9-3]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/in-9-3-vote-expert-panel-backs-intermunes-pirfenidone/feed</wfw:commentRss>
		</item>
		<item>
		<title>Abbott buys Facet Biotech for $450M</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/abbott-buys-facet-biotech-for-450m</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/abbott-buys-facet-biotech-for-450m#comments</comments>
		<pubDate>Wed, 10 Mar 2010 02:47:06 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[abbott-labs]]></category>

		<category><![CDATA[acquisition]]></category>

		<category><![CDATA[biogen]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[biotech deals]]></category>

		<category><![CDATA[data]]></category>

		<category><![CDATA[french]]></category>

		<category><![CDATA[mergers and acquisitions]]></category>

		<category><![CDATA[optics]]></category>

		<category><![CDATA[percent-premium]]></category>

		<category><![CDATA[pirfenidone]]></category>

		<category><![CDATA[strengthen]]></category>

		<category><![CDATA[transgene]]></category>

		<category><![CDATA[white]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/abbott-buys-facet-biotech-for-450m</guid>
		<description><![CDATA[ Abbott has succeeded where Biogen Idec once failed . The company announced late Tuesday that it's purchasing]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/abbott-buys-facet-biotech-for-450m/feed</wfw:commentRss>
		</item>
		<item>
		<title>Making Sense Out Pharma DTC Spending Trends</title>
		<link>http://pharma-marketer.brollyclient.ca/traditional-strategies/making-sense-out-pharma-dtc-spending-trends</link>
		<comments>http://pharma-marketer.brollyclient.ca/traditional-strategies/making-sense-out-pharma-dtc-spending-trends#comments</comments>
		<pubDate>Wed, 10 Mar 2010 00:11:41 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Traditional Strategies]]></category>

		<category><![CDATA[Web Marketing]]></category>

		<category><![CDATA[ad spend]]></category>

		<category><![CDATA[DTC]]></category>

		<category><![CDATA[dtc advertising]]></category>

		<category><![CDATA[internet]]></category>

		<category><![CDATA[internet-table]]></category>

		<category><![CDATA[kantar-media]]></category>

		<category><![CDATA[marketing]]></category>

		<category><![CDATA[math]]></category>

		<category><![CDATA[media]]></category>

		<category><![CDATA[nielsen]]></category>

		<category><![CDATA[numbers]]></category>

		<category><![CDATA[search-engine]]></category>

		<category><![CDATA[table]]></category>

		<category><![CDATA[total]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/making-sense-out-pharma-dtc-spending-trends</guid>
		<description><![CDATA[ePharma boosters see the latest direct-to-consumer (DTC) advertising spending numbers as a positive sign that the drug industry is finally increasing its allotment to the Internet in its DTC marketing budget. Nielsen data indicate that "spending on Internet ads, which has doubled over the last five years, hit $117.4 million, up 31 percent" (see " Drugmakers boost consumer ad spending 2 pct in '09 "). Total DTC spending increased 1.9% in 2009 vs. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/traditional-strategies/making-sense-out-pharma-dtc-spending-trends/feed</wfw:commentRss>
		</item>
		<item>
		<title>BD – too many unnecessary visits?</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/bd-%e2%80%93-too-many-unnecessary-visits</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/bd-%e2%80%93-too-many-unnecessary-visits#comments</comments>
		<pubDate>Tue, 09 Mar 2010 23:07:18 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[all-people]]></category>

		<category><![CDATA[diagnostics]]></category>

		<category><![CDATA[helping]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[live-healthy]]></category>

		<category><![CDATA[north america]]></category>

		<category><![CDATA[patients]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[single-page]]></category>

		<category><![CDATA[test-causing]]></category>

		<category><![CDATA[the-largest]]></category>

		<category><![CDATA[your-patients]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/bd-%e2%80%93-too-many-unnecessary-visits</guid>
		<description><![CDATA[ Is your Pap test causing your patients too many unnecessary visits? Brand name: BD Diagnostics Generic name/category: Diagnostics Company: BD Diagnostics Country/Market: USA, North America Indication(s)/use: Pap Test Target: Healthcare professionals (HCP) Tagline: Helping all people live healthy lives Medium: Print ad Size/duration: Single-page Publication/Aired: March 2010 To see all of this brand&#8217;s ads on AdPharm, click here Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/bd-%e2%80%93-too-many-unnecessary-visits/feed</wfw:commentRss>
		</item>
		<item>
		<title>Who is the Reigning Social Media Champ Between Google and Yahoo?</title>
		<link>http://pharma-marketer.brollyclient.ca/internet-marketing/who-is-the-reigning-social-media-champ-between-google-and-yahoo</link>
		<comments>http://pharma-marketer.brollyclient.ca/internet-marketing/who-is-the-reigning-social-media-champ-between-google-and-yahoo#comments</comments>
		<pubDate>Tue, 09 Mar 2010 21:24:37 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Web Marketing]]></category>

		<category><![CDATA[advanced-social]]></category>

		<category><![CDATA[both-work]]></category>

		<category><![CDATA[facebook]]></category>

		<category><![CDATA[facebook-connect]]></category>

		<category><![CDATA[failed]]></category>

		<category><![CDATA[following-the-failed]]></category>

		<category><![CDATA[google-buzz]]></category>

		<category><![CDATA[recently-announced]]></category>

		<category><![CDATA[Social Media]]></category>

		<category><![CDATA[social media strategy]]></category>

		<category><![CDATA[uses-in-house]]></category>

		<category><![CDATA[yahoo]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/who-is-the-reigning-social-media-champ-between-google-and-yahoo</guid>
		<description><![CDATA[When it comes to social media, Yahoo and Google have differing strategies but both work well. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/internet-marketing/who-is-the-reigning-social-media-champ-between-google-and-yahoo/feed</wfw:commentRss>
		</item>
		<item>
		<title>Gelnique – weapon against wetting</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/gelnique-%e2%80%93-weapon-against-wetting</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/gelnique-%e2%80%93-weapon-against-wetting#comments</comments>
		<pubDate>Tue, 09 Mar 2010 21:00:53 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[against-wetting]]></category>

		<category><![CDATA[cover-overlay]]></category>

		<category><![CDATA[four-page]]></category>

		<category><![CDATA[her-weapon]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[overactive]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[smart]]></category>

		<category><![CDATA[technology]]></category>

		<category><![CDATA[usa]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/gelnique-%e2%80%93-weapon-against-wetting</guid>
		<description><![CDATA[ Her weapon against wetting Brand name: Gelnique Generic name/category: Oxybutynin, urology Company: Watson Country/Market: USA, North America Indication(s)/use: Overactive bladder (OAB) Target: Healthcare Professionals (HCP) Tagline: Smart gel technology is her weapon against wetting Medium: Print ad Size/duration: Four-page cover overlay Publication/Aired: March 2010 To see all of this brand&#8217;s ads on AdPharm, click here Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/gelnique-%e2%80%93-weapon-against-wetting/feed</wfw:commentRss>
		</item>
		<item>
		<title>Tocagen raises $7.8M; ISTA gets PDUFA date;</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/tocagen-raises-78m-ista-gets-pdufa-date</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/tocagen-raises-78m-ista-gets-pdufa-date#comments</comments>
		<pubDate>Tue, 09 Mar 2010 18:56:09 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[abbott-labs]]></category>

		<category><![CDATA[agency]]></category>

		<category><![CDATA[bacteria]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[biotech deals]]></category>

		<category><![CDATA[keata-pharma]]></category>

		<category><![CDATA[optics]]></category>

		<category><![CDATA[percent-premium]]></category>

		<category><![CDATA[pivotal]]></category>

		<category><![CDATA[public-biotechs]]></category>

		<category><![CDATA[strengthen]]></category>

		<category><![CDATA[the-bacteria]]></category>

		<category><![CDATA[transgene]]></category>

		<category><![CDATA[two-part-sale]]></category>

		<category><![CDATA[white]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/tocagen-raises-78m-ista-gets-pdufa-date</guid>
		<description><![CDATA[ ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/tocagen-raises-78m-ista-gets-pdufa-date/feed</wfw:commentRss>
		</item>
		<item>
		<title>AutoImmune calls it quits</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/autoimmune-calls-it-quits</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/autoimmune-calls-it-quits#comments</comments>
		<pubDate>Tue, 09 Mar 2010 18:29:28 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[agency]]></category>

		<category><![CDATA[article]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[biotech deals]]></category>

		<category><![CDATA[biotech graveyard]]></category>

		<category><![CDATA[its-operations]]></category>

		<category><![CDATA[other-tangible]]></category>

		<category><![CDATA[the-bacteria]]></category>

		<category><![CDATA[two-part-sale]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/autoimmune-calls-it-quits</guid>
		<description><![CDATA[ After considering all of]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/autoimmune-calls-it-quits/feed</wfw:commentRss>
		</item>
		<item>
		<title>Cellzome partners with GSK on inflammatory diseases</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/cellzome-partners-with-gsk-on-inflammatory-diseases</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/cellzome-partners-with-gsk-on-inflammatory-diseases#comments</comments>
		<pubDate>Tue, 09 Mar 2010 18:24:11 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[arsalan-arif]]></category>

		<category><![CDATA[article]]></category>

		<category><![CDATA[bayer-health]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[biotech deals]]></category>

		<category><![CDATA[cellzome]]></category>

		<category><![CDATA[discovery-pact]]></category>

		<category><![CDATA[glaxosmithkline]]></category>

		<category><![CDATA[other-tangible]]></category>

		<category><![CDATA[partnership]]></category>

		<category><![CDATA[pharmaceutical]]></category>

		<category><![CDATA[the-companies]]></category>

		<category><![CDATA[under-the-terms]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/cellzome-partners-with-gsk-on-inflammatory-diseases</guid>
		<description><![CDATA[ Germany's Cellzome has inked a second drug discovery pact with GlaxoSmithKline in the field of inflammatory disease. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/cellzome-partners-with-gsk-on-inflammatory-diseases/feed</wfw:commentRss>
		</item>
		<item>
		<title>Facebook and Web Pages - What Pharma and FDA Need to Know</title>
		<link>http://pharma-marketer.brollyclient.ca/regulatory-and-compliance/facebook-and-web-pages-what-pharma-and-fda-need-to-know</link>
		<comments>http://pharma-marketer.brollyclient.ca/regulatory-and-compliance/facebook-and-web-pages-what-pharma-and-fda-need-to-know#comments</comments>
		<pubDate>Tue, 09 Mar 2010 18:17:40 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Regulatory]]></category>

		<category><![CDATA[agency]]></category>

		<category><![CDATA[breakneck-speed]]></category>

		<category><![CDATA[bringing-people]]></category>

		<category><![CDATA[environment]]></category>

		<category><![CDATA[facebook]]></category>

		<category><![CDATA[huge-proportion]]></category>

		<category><![CDATA[people]]></category>

		<category><![CDATA[product-related]]></category>

		<category><![CDATA[public-health]]></category>

		<category><![CDATA[roads-or-public]]></category>

		<category><![CDATA[slowly-grapples]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/facebook-and-web-pages-what-pharma-and-fda-need-to-know</guid>
		<description><![CDATA[ ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/regulatory-and-compliance/facebook-and-web-pages-what-pharma-and-fda-need-to-know/feed</wfw:commentRss>
		</item>
		<item>
		<title>Who&#8217;s the next biotech buyout target?</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/whos-the-next-biotech-buyout-target</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/whos-the-next-biotech-buyout-target#comments</comments>
		<pubDate>Tue, 09 Mar 2010 18:04:11 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[arsalan-arif]]></category>

		<category><![CDATA[bayer-health]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[biotechs-biogen]]></category>

		<category><![CDATA[blockbuster]]></category>

		<category><![CDATA[cellzome]]></category>

		<category><![CDATA[drug]]></category>

		<category><![CDATA[glaxosmithkline]]></category>

		<category><![CDATA[haggling-over]]></category>

		<category><![CDATA[indications]]></category>

		<category><![CDATA[most-expensive]]></category>

		<category><![CDATA[other-tangible]]></category>

		<category><![CDATA[partnership]]></category>

		<category><![CDATA[under-the-terms]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/whos-the-next-biotech-buyout-target</guid>
		<description><![CDATA[ With Astellas Pharma and OSI Pharmaceuticals haggling over price, BNet Pharma wonders which biotechs could be next on the buyout menu. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/whos-the-next-biotech-buyout-target/feed</wfw:commentRss>
		</item>
		<item>
		<title>Citracal – Recent finding</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/citracal-%e2%80%93-recent-finding</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/citracal-%e2%80%93-recent-finding#comments</comments>
		<pubDate>Tue, 09 Mar 2010 18:00:03 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[bayer]]></category>

		<category><![CDATA[calcium]]></category>

		<category><![CDATA[calcium-may]]></category>

		<category><![CDATA[citracal]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[not-effectively]]></category>

		<category><![CDATA[single-page]]></category>

		<category><![CDATA[the-largest]]></category>

		<category><![CDATA[usa]]></category>

		<category><![CDATA[women-taking]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/citracal-%e2%80%93-recent-finding</guid>
		<description><![CDATA[ Recent finding: > 50% of women taking calcium may not effectively absorb it because they don&#8217;t take it with a meal Brand name: Citracal Generic name/category: Calcium citrate Company: Bayer Healthcare Country/Market: USA, North America Indication(s)/use: Calcium deficiency Target: Healthcare Professionals (HCP) Tagline: n/a Medium: Print ad Size/duration: Single-page Publication/Aired: March 2010 To see all of this brand&#8217;s ads on AdPharm, click here Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/citracal-%e2%80%93-recent-finding/feed</wfw:commentRss>
		</item>
		<item>
		<title>InterMune trading halted on panel review</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/intermune-trading-halted-on-panel-review</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/intermune-trading-halted-on-panel-review#comments</comments>
		<pubDate>Tue, 09 Mar 2010 17:08:25 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[advisory-committee]]></category>

		<category><![CDATA[allergy-drugs]]></category>

		<category><![CDATA[arsalan-arif]]></category>

		<category><![CDATA[bayer-health]]></category>

		<category><![CDATA[biotechs-biogen]]></category>

		<category><![CDATA[committee]]></category>

		<category><![CDATA[meeting-today]]></category>

		<category><![CDATA[nda]]></category>

		<category><![CDATA[other-tangible]]></category>

		<category><![CDATA[partnership]]></category>

		<category><![CDATA[under-the-terms]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/intermune-trading-halted-on-panel-review</guid>
		<description><![CDATA[ The Pulmonary-Allergy Drugs Advisory Committee is meeting today to review InterMune's NDA for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis. As a result, trading of the company's stock has been halted]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/intermune-trading-halted-on-panel-review/feed</wfw:commentRss>
		</item>
		<item>
		<title>Canesten – Sock it to ‘em!</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/canesten-%e2%80%93-sock-it-to-%e2%80%98em</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/canesten-%e2%80%93-sock-it-to-%e2%80%98em#comments</comments>
		<pubDate>Tue, 09 Mar 2010 17:00:04 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adamovi]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[bayer]]></category>

		<category><![CDATA[bratislava]]></category>

		<category><![CDATA[clotrimazole]]></category>

		<category><![CDATA[director]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[single-page]]></category>

		<category><![CDATA[the-largest]]></category>

		<category><![CDATA[usa]]></category>

		<category><![CDATA[world]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/canesten-%e2%80%93-sock-it-to-%e2%80%98em</guid>
		<description><![CDATA[ Foot problems itching you? Sock it to &#8216;em! Agency: MARK BBDO, Bratislava, Slovakia Creative Director: Dávid Slimák Art Director: Lukáš Karásek Copywriter: Juraj Chmel Account manager: Dana Adamovi ová Brand name: Canesten Generic name/category: Clotrimazole Company: Bayer Healthcare Country/Market: Slovakia, Europe Indication(s)/use: athlete&#8217;s foot and jock itch Target: Consumers (DTC) Tagline: Sock it to &#8216;em! Medium: Print ad Size/duration: Single-page / Poster Publication/Aired: September 2009 Source: Ads of the World To see all of this brand&#8217;s ads on AdPharm, click here Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/canesten-%e2%80%93-sock-it-to-%e2%80%98em/feed</wfw:commentRss>
		</item>
		<item>
		<title>20 Drug sales reps a week ?</title>
		<link>http://pharma-marketer.brollyclient.ca/dtc/20-drug-sales-reps-a-week</link>
		<comments>http://pharma-marketer.brollyclient.ca/dtc/20-drug-sales-reps-a-week#comments</comments>
		<pubDate>Tue, 09 Mar 2010 16:04:45 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[DTC]]></category>

		<category><![CDATA[amazed-at-drug]]></category>

		<category><![CDATA[change-business]]></category>

		<category><![CDATA[doctor]]></category>

		<category><![CDATA[drug-companies]]></category>

		<category><![CDATA[drug-industry]]></category>

		<category><![CDATA[growing-more]]></category>

		<category><![CDATA[make-their]]></category>

		<category><![CDATA[physicians-were]]></category>

		<category><![CDATA[practices]]></category>

		<category><![CDATA[sales]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/20-drug-sales-reps-a-week</guid>
		<description><![CDATA[How many times have you been waiting to see your doctor and observed a sales rep come in, drop off samples and leave. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/dtc/20-drug-sales-reps-a-week/feed</wfw:commentRss>
		</item>
		<item>
		<title>Apaisyl – TV commercial</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/apaisyl-%e2%80%93-tv-commercial</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/apaisyl-%e2%80%93-tv-commercial#comments</comments>
		<pubDate>Tue, 09 Mar 2010 16:00:01 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[bedroom]]></category>

		<category><![CDATA[consumers]]></category>

		<category><![CDATA[DTC]]></category>

		<category><![CDATA[eating-lice]]></category>

		<category><![CDATA[europe]]></category>

		<category><![CDATA[hair]]></category>

		<category><![CDATA[her-head]]></category>

		<category><![CDATA[isothipendyl]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[the-largest]]></category>

		<category><![CDATA[votre-peau]]></category>

		<category><![CDATA[young-girl]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/apaisyl-%e2%80%93-tv-commercial</guid>
		<description><![CDATA[ A young girl is reading a book in her bedroom. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/apaisyl-%e2%80%93-tv-commercial/feed</wfw:commentRss>
		</item>
		<item>
		<title>A GSK/Sirtris Wrap-Up</title>
		<link>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/a-gsksirtris-wrap-up</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/a-gsksirtris-wrap-up#comments</comments>
		<pubDate>Tue, 09 Mar 2010 15:46:28 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[In the Pipeline]]></category>

		<category><![CDATA[because-someone]]></category>

		<category><![CDATA[biotechnology]]></category>

		<category><![CDATA[detractors]]></category>

		<category><![CDATA[experts]]></category>

		<category><![CDATA[involve-sirtuin]]></category>

		<category><![CDATA[mechanism]]></category>

		<category><![CDATA[nature]]></category>

		<category><![CDATA[publication]]></category>

		<category><![CDATA[reported]]></category>

		<category><![CDATA[says-the-group]]></category>

		<category><![CDATA[sirtris]]></category>

		<category><![CDATA[targets]]></category>

		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/a-gsksirtris-wrap-up</guid>
		<description><![CDATA[ Nature Biotechnology weighs in on the GSK/Sirtris controversy. They have a lot of good information, and I'm not just saying that because someone there has clearly read over the comments that have showed up to my posts on the subject. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/a-gsksirtris-wrap-up/feed</wfw:commentRss>
		</item>
		<item>
		<title>Hope Darn Well Springs Eternal</title>
		<link>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/hope-darn-well-springs-eternal</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/hope-darn-well-springs-eternal#comments</comments>
		<pubDate>Tue, 09 Mar 2010 15:22:36 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[In the Pipeline]]></category>

		<category><![CDATA[business and markets]]></category>

		<category><![CDATA[clinical-trials]]></category>

		<category><![CDATA[collapse]]></category>

		<category><![CDATA[drug-discovery]]></category>

		<category><![CDATA[foolhardy]]></category>

		<category><![CDATA[major-customer]]></category>

		<category><![CDATA[medivation]]></category>

		<category><![CDATA[really-the-kind]]></category>

		<category><![CDATA[twice-as-deep]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/hope-darn-well-springs-eternal</guid>
		<description><![CDATA[ Well, it takes all kinds to make a market. And the collapse in Medivation's shares after their disastrous Phase III results the other day seem to have brought out some hopeful buyers. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/hope-darn-well-springs-eternal/feed</wfw:commentRss>
		</item>
		<item>
		<title>Azyter – efficace, simple et court</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/azyter-%e2%80%93-efficace-simple-et-court</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/azyter-%e2%80%93-efficace-simple-et-court#comments</comments>
		<pubDate>Tue, 09 Mar 2010 15:00:58 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[consumers]]></category>

		<category><![CDATA[DTC]]></category>

		<category><![CDATA[efficace]]></category>

		<category><![CDATA[hair]]></category>

		<category><![CDATA[hcp]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[moteur]]></category>

		<category><![CDATA[online-pharmaceutical]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[votre-peau]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/azyter-%e2%80%93-efficace-simple-et-court</guid>
		<description><![CDATA[ Collyre antibiotique Efficace, simple et court Brand name: Azyter Generic name/category: collyrium lotion and Azithromycin Company: Laboratoires ThÃ©a Country/Market: France, Europe Indication(s)/use: bacterial conjunctivitis Target: Healthcare Professionals (HCP) Tagline: Moteur d&#8217;innovations Medium: Print ad Size/duration: Single-page Publication/Aired: March 2010 Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/azyter-%e2%80%93-efficace-simple-et-court/feed</wfw:commentRss>
		</item>
		<item>
		<title>&#8216;Externalization&#8217; takes center stage at Bio-Europe Spring</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/externalization-takes-center-stage-at-bio-europe-spring</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/externalization-takes-center-stage-at-bio-europe-spring#comments</comments>
		<pubDate>Tue, 09 Mar 2010 14:48:51 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[advisory-committee]]></category>

		<category><![CDATA[biotechs-biogen]]></category>

		<category><![CDATA[earn-on-their]]></category>

		<category><![CDATA[made-it-crystal]]></category>

		<category><![CDATA[meeting-today]]></category>

		<category><![CDATA[morgan-stanley]]></category>

		<category><![CDATA[nda]]></category>

		<category><![CDATA[partnership]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/externalization-takes-center-stage-at-bio-europe-spring</guid>
		<description><![CDATA[ BARCELONA - The emphasis in the European biopharma scene is squarely on finding a new equation for drug discovery that relies less on]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/externalization-takes-center-stage-at-bio-europe-spring/feed</wfw:commentRss>
		</item>
		<item>
		<title>Ark in sales talks after regulators demand new trial</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/ark-in-sales-talks-after-regulators-demand-new-trial</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/ark-in-sales-talks-after-regulators-demand-new-trial#comments</comments>
		<pubDate>Tue, 09 Mar 2010 13:09:57 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[advisory-committee]]></category>

		<category><![CDATA[article]]></category>

		<category><![CDATA[biotechs-biogen]]></category>

		<category><![CDATA[earn-on-their]]></category>

		<category><![CDATA[morgan-stanley]]></category>

		<category><![CDATA[partnership]]></category>

		<category><![CDATA[potential]]></category>

		<category><![CDATA[their-potential]]></category>

		<category><![CDATA[therapeutics]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/ark-in-sales-talks-after-regulators-demand-new-trial</guid>
		<description><![CDATA[ London-based Ark Therapeutics' efforts to pioneer a gene-based brain cancer therapy in Europe hit a new hurdle today as European regulators demanded a new trial of Cerepro ahead of any approval. Ark pulled its marketing application, which had been rejected last December, and says it's considering selling the company. An expert advisory panel for the European Medicines Agency decided at the end of last year that Cerepro failed to measure up to its efficacy standards]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/ark-in-sales-talks-after-regulators-demand-new-trial/feed</wfw:commentRss>
		</item>
		<item>
		<title>Zyrtec - dust</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/zyrtec-dust</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/zyrtec-dust#comments</comments>
		<pubDate>Tue, 09 Mar 2010 13:04:16 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/zyrtec-dust</guid>
		<description><![CDATA[ Click here to see the ad ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/zyrtec-dust/feed</wfw:commentRss>
		</item>
		<item>
		<title>Exelixis chops 270 jobs in restructuring</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/exelixis-chops-270-jobs-in-restructuring</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/exelixis-chops-270-jobs-in-restructuring#comments</comments>
		<pubDate>Tue, 09 Mar 2010 10:25:58 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[advisory-committee]]></category>

		<category><![CDATA[autoimmune-pact]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[exelixis]]></category>

		<category><![CDATA[focus-on-three]]></category>

		<category><![CDATA[francisco-based]]></category>

		<category><![CDATA[its-preclinical]]></category>

		<category><![CDATA[layoffs]]></category>

		<category><![CDATA[million-through]]></category>

		<category><![CDATA[morgan-stanley]]></category>

		<category><![CDATA[potential]]></category>

		<category><![CDATA[shares-advance]]></category>

		<category><![CDATA[the-anticipated]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/exelixis-chops-270-jobs-in-restructuring</guid>
		<description><![CDATA[ South San Francisco-based Exelixis is axing 270 jobs--40 percent of its workforce--as it circles its wagons around its top three cancer programs. Citing SEC documents, the San Francisco Business Times reports that the axe will fall hardest on the company's drug discovery unit. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/exelixis-chops-270-jobs-in-restructuring/feed</wfw:commentRss>
		</item>
		<item>
		<title>Urocit-K 15 – kidney stones hurt</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/urocit-k-15-%e2%80%93-kidney-stones-hurt</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/urocit-k-15-%e2%80%93-kidney-stones-hurt#comments</comments>
		<pubDate>Tue, 09 Mar 2010 00:00:16 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[north america]]></category>

		<category><![CDATA[potassium]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[the-largest]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/urocit-k-15-%e2%80%93-kidney-stones-hurt</guid>
		<description><![CDATA[ Kidney stones hurt. Noncompliance can hurt more. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/urocit-k-15-%e2%80%93-kidney-stones-hurt/feed</wfw:commentRss>
		</item>
		<item>
		<title>Efexor-Exel</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/efexor-exel</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/efexor-exel#comments</comments>
		<pubDate>Mon, 08 Mar 2010 23:00:19 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[belgium]]></category>

		<category><![CDATA[disorder]]></category>

		<category><![CDATA[europe]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[major]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[single-page]]></category>

		<category><![CDATA[the-largest]]></category>

		<category><![CDATA[venlafaxine]]></category>

		<category><![CDATA[wyeth]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/efexor-exel</guid>
		<description><![CDATA[ Efexor-Exel Brand name: Efexor-Exel Generic name/category: Venlafaxine Company: Wyeth Country/Market: Belgium, Europe Indication(s)/use: Major Depressive Disorder Target: Healthcare Professionals (HCP) Tagline: n/a Medium: Print ad Size/duration: Single-page Publication/Aired: January 2010 To see all of this brand&#8217;s ads on AdPharm, click here Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/efexor-exel/feed</wfw:commentRss>
		</item>
		<item>
		<title>Bad News at Exelixis</title>
		<link>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/bad-news-at-exelixis</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/bad-news-at-exelixis#comments</comments>
		<pubDate>Mon, 08 Mar 2010 21:51:44 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[In the Pipeline]]></category>

		<category><![CDATA[all-departments]]></category>

		<category><![CDATA[area-biotech]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[exelixis]]></category>

		<category><![CDATA[from-the-sound]]></category>

		<category><![CDATA[help-it-one]]></category>

		<category><![CDATA[its-healthiest]]></category>

		<category><![CDATA[scene-doesn]]></category>

		<category><![CDATA[sound]]></category>

		<category><![CDATA[the-numbers]]></category>

		<category><![CDATA[their-work]]></category>

		<category><![CDATA[work]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/bad-news-at-exelixis</guid>
		<description><![CDATA[ I'm hearing from more than one source that Exelixis has laid off about 40% of their work force, which is somewhere around 250 people (the numbers I get don't all agree). This seems to be across the board, all departments, and most everyone is being asked to leave today]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/bad-news-at-exelixis/feed</wfw:commentRss>
		</item>
		<item>
		<title>Complimentary Web Seminar: Leverage Facebook to Improve Brand Awareness and Promote Patient Advocacy</title>
		<link>http://pharma-marketer.brollyclient.ca/internet-marketing/complimentary-web-seminar-leverage-facebook-to-improve-brand-awareness-and-promote-patient-advocacy</link>
		<comments>http://pharma-marketer.brollyclient.ca/internet-marketing/complimentary-web-seminar-leverage-facebook-to-improve-brand-awareness-and-promote-patient-advocacy#comments</comments>
		<pubDate>Mon, 08 Mar 2010 21:37:25 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Web Marketing]]></category>

		<category><![CDATA[adhd allies]]></category>

		<category><![CDATA[advocacy]]></category>

		<category><![CDATA[facebook]]></category>

		<category><![CDATA[hear-how]]></category>

		<category><![CDATA[improve]]></category>

		<category><![CDATA[johnson and johnson]]></category>

		<category><![CDATA[p1606]]></category>

		<category><![CDATA[patient advocacy]]></category>

		<category><![CDATA[priority-code]]></category>

		<category><![CDATA[promote]]></category>

		<category><![CDATA[promote-patient]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/complimentary-web-seminar-leverage-facebook-to-improve-brand-awareness-and-promote-patient-advocacy</guid>
		<description><![CDATA[Title: Leverage Facebook to Improve Brand Awareness and Promote Patient AdvocacyDate: Wednesday, March 24, 2010Time: 2:00 PM - 3:00 PM EDTRegister here: https://www1.gotomeeting.com/register/241889944Mention priority code P1606W1Twitter/BlogAbout the web seminar:In this web seminar, you'll hear how McNeil Pediatrics created 2 successful Facebook communities ADHD MomsTM and ADHD AlliesTM, to]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/internet-marketing/complimentary-web-seminar-leverage-facebook-to-improve-brand-awareness-and-promote-patient-advocacy/feed</wfw:commentRss>
		</item>
		<item>
		<title>SensiGene – Transcending New Heights With Breakthrough Technology.</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/sensigene-%e2%80%93-transcending-new-heights-with-breakthrough-technology</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/sensigene-%e2%80%93-transcending-new-heights-with-breakthrough-technology#comments</comments>
		<pubDate>Mon, 08 Mar 2010 21:15:14 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[breakthrough]]></category>

		<category><![CDATA[heights]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[molecular]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[sequenom]]></category>

		<category><![CDATA[single-page]]></category>

		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/sensigene-%e2%80%93-transcending-new-heights-with-breakthrough-technology</guid>
		<description><![CDATA[ Transcending New Heights With Breakthrough Technology. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/sensigene-%e2%80%93-transcending-new-heights-with-breakthrough-technology/feed</wfw:commentRss>
		</item>
		<item>
		<title>sanofi aventis Feels the Social Media Pain. But Is It Authentic?</title>
		<link>http://pharma-marketer.brollyclient.ca/traditional-strategies/sanofi-aventis-feels-the-social-media-pain-but-is-it-authentic</link>
		<comments>http://pharma-marketer.brollyclient.ca/traditional-strategies/sanofi-aventis-feels-the-social-media-pain-but-is-it-authentic#comments</comments>
		<pubDate>Mon, 08 Mar 2010 20:54:19 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Traditional Strategies]]></category>

		<category><![CDATA[complaints]]></category>

		<category><![CDATA[conversation]]></category>

		<category><![CDATA[disfigurment]]></category>

		<category><![CDATA[dtc advertising]]></category>

		<category><![CDATA[facebook]]></category>

		<category><![CDATA[industries]]></category>

		<category><![CDATA[internet]]></category>

		<category><![CDATA[marketing]]></category>

		<category><![CDATA[media]]></category>

		<category><![CDATA[motivations]]></category>

		<category><![CDATA[Social Media]]></category>

		<category><![CDATA[taxotere]]></category>

		<category><![CDATA[total]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/sanofi-aventis-feels-the-social-media-pain-but-is-it-authentic</guid>
		<description><![CDATA[Simultaneous posts on Pharmalot and Pharma bnet have focused on what seems to be a disgruntled patient who posted photos and comments on sanofi-aventis's (S-A) Facebook page (see " Bald Women Lash Out At Sanofi-Aventis &#038; Taxotere " and " Sanofi's Latest Challenge: Women Who Say Its Chemotherapy Left Them Permanently Bald "). ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/traditional-strategies/sanofi-aventis-feels-the-social-media-pain-but-is-it-authentic/feed</wfw:commentRss>
		</item>
		<item>
		<title>&#34;I will never go away&#34;  The downside of using social media for health</title>
		<link>http://pharma-marketer.brollyclient.ca/dtc/i-will-never-go-away-the-downside-of-using-social-media-for-health</link>
		<comments>http://pharma-marketer.brollyclient.ca/dtc/i-will-never-go-away-the-downside-of-using-social-media-for-health#comments</comments>
		<pubDate>Mon, 08 Mar 2010 20:19:37 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[DTC]]></category>

		<category><![CDATA[drug]]></category>

		<category><![CDATA[hair]]></category>

		<category><![CDATA[having-the-drug]]></category>

		<category><![CDATA[sanofi-on-their]]></category>

		<category><![CDATA[Social Media]]></category>

		<category><![CDATA[taxotere]]></category>

		<category><![CDATA[the-patient]]></category>

		<category><![CDATA[women]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/i-will-never-go-away-the-downside-of-using-social-media-for-health</guid>
		<description><![CDATA[An upset patient who has decided to challenge Sanofi on their side effects. Was she informed ? On the Taxotere web page hair loss is listed as a side effect in the fair balance as; Other common side effects from Taxotere]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/dtc/i-will-never-go-away-the-downside-of-using-social-media-for-health/feed</wfw:commentRss>
		</item>
		<item>
		<title>SensiGene – An Advanced Alternative in Prenatal Care</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/sensigene-%e2%80%93-an-advanced-alternative-in-prenatal-care</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/sensigene-%e2%80%93-an-advanced-alternative-in-prenatal-care#comments</comments>
		<pubDate>Mon, 08 Mar 2010 20:00:12 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[breakthrough]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[molecular]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[sequenom]]></category>

		<category><![CDATA[single-page]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/sensigene-%e2%80%93-an-advanced-alternative-in-prenatal-care</guid>
		<description><![CDATA[ An Advanced Alternative in Prenatal Care Brand name: Sequenom CMM Generic name/category: Service Industry Company: Sequenom CMM Country/Market: USA, North America Indication(s)/use: Molecular diagnostics, Cystic Fibrosis Target: Healthcare Professionals (HCP) / Trade Tagline: n/a Medium: Print ad Size/duration: Single-page Publication/Aired: The Journal of Molecular Diagnostics &#8211; June 2009 To see all of this brand&#8217;s ads on AdPharm, click here Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/sensigene-%e2%80%93-an-advanced-alternative-in-prenatal-care/feed</wfw:commentRss>
		</item>
		<item>
		<title>Enbrel - clearer skin</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/enbrel-clearer-skin</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/enbrel-clearer-skin#comments</comments>
		<pubDate>Mon, 08 Mar 2010 19:33:23 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/enbrel-clearer-skin</guid>
		<description><![CDATA[ Click here to see the ad ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/enbrel-clearer-skin/feed</wfw:commentRss>
		</item>
		<item>
		<title>Cervarix - maintenant offert</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/cervarix-maintenant-offert</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/cervarix-maintenant-offert#comments</comments>
		<pubDate>Mon, 08 Mar 2010 19:33:19 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/cervarix-maintenant-offert</guid>
		<description><![CDATA[ Click here to see the ad ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/cervarix-maintenant-offert/feed</wfw:commentRss>
		</item>
		<item>
		<title>Aleve - fewer pills</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/aleve-fewer-pills</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/aleve-fewer-pills#comments</comments>
		<pubDate>Mon, 08 Mar 2010 19:33:17 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/aleve-fewer-pills</guid>
		<description><![CDATA[ Click here to see the ad ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/aleve-fewer-pills/feed</wfw:commentRss>
		</item>
		<item>
		<title>Ockham’s Razor Meets Pharma Marketing</title>
		<link>http://pharma-marketer.brollyclient.ca/internet-marketing/ockham%e2%80%99s-razor-meets-pharma-marketing</link>
		<comments>http://pharma-marketer.brollyclient.ca/internet-marketing/ockham%e2%80%99s-razor-meets-pharma-marketing#comments</comments>
		<pubDate>Mon, 08 Mar 2010 18:59:26 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Web Marketing]]></category>

		<category><![CDATA[marketing]]></category>

		<category><![CDATA[message]]></category>

		<category><![CDATA[network]]></category>

		<category><![CDATA[opinion]]></category>

		<category><![CDATA[pharma]]></category>

		<category><![CDATA[search-engine]]></category>

		<category><![CDATA[social]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/ockham%e2%80%99s-razor-meets-pharma-marketing</guid>
		<description><![CDATA[ Ockham&#8217;s Razor: Pluralitas non est ponenda sine necessitate; “Plurality should not be posited without necessity.” The principle gives precedence to simplicity; of two competing theories, the simplest explanation of an entity is to be preferred. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/internet-marketing/ockham%e2%80%99s-razor-meets-pharma-marketing/feed</wfw:commentRss>
		</item>
		<item>
		<title>Interesting History at FDA as Alliance for a Stronger FDA Goes to Bat for Bigger Agency Budget</title>
		<link>http://pharma-marketer.brollyclient.ca/regulatory-and-compliance/interesting-history-at-fda-as-alliance-for-a-stronger-fda-goes-to-bat-for-bigger-agency-budget</link>
		<comments>http://pharma-marketer.brollyclient.ca/regulatory-and-compliance/interesting-history-at-fda-as-alliance-for-a-stronger-fda-goes-to-bat-for-bigger-agency-budget#comments</comments>
		<pubDate>Mon, 08 Mar 2010 18:22:19 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Regulatory]]></category>

		<category><![CDATA[breakneck-speed]]></category>

		<category><![CDATA[bringing-people]]></category>

		<category><![CDATA[environment]]></category>

		<category><![CDATA[from-the-same]]></category>

		<category><![CDATA[huge-proportion]]></category>

		<category><![CDATA[previous]]></category>

		<category><![CDATA[resources]]></category>

		<category><![CDATA[roads-or-public]]></category>

		<category><![CDATA[slowly-grapples]]></category>

		<category><![CDATA[smart-messaging]]></category>

		<category><![CDATA[times-as-large]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/interesting-history-at-fda-as-alliance-for-a-stronger-fda-goes-to-bat-for-bigger-agency-budget</guid>
		<description><![CDATA[ ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/regulatory-and-compliance/interesting-history-at-fda-as-alliance-for-a-stronger-fda-goes-to-bat-for-bigger-agency-budget/feed</wfw:commentRss>
		</item>
		<item>
		<title>ExonHit, bioMerieux nix colon cancer program</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/exonhit-biomerieux-nix-colon-cancer-program</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/exonhit-biomerieux-nix-colon-cancer-program#comments</comments>
		<pubDate>Mon, 08 Mar 2010 18:16:13 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[collaborations]]></category>

		<category><![CDATA[efforts]]></category>

		<category><![CDATA[european]]></category>

		<category><![CDATA[exelixis]]></category>

		<category><![CDATA[from-the-colon]]></category>

		<category><![CDATA[its-preclinical]]></category>

		<category><![CDATA[million-through]]></category>

		<category><![CDATA[shares-advance]]></category>

		<category><![CDATA[the-anticipated]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/exonhit-biomerieux-nix-colon-cancer-program</guid>
		<description><![CDATA[ French drugmakers ExonHit Therapeutics and bioM]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/exonhit-biomerieux-nix-colon-cancer-program/feed</wfw:commentRss>
		</item>
		<item>
		<title>FDA OKs Cell Therapeutics&#8217; manufacturing plant</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/fda-oks-cell-therapeutics-manufacturing-plant</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/fda-oks-cell-therapeutics-manufacturing-plant#comments</comments>
		<pubDate>Mon, 08 Mar 2010 18:01:44 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[collaborations]]></category>

		<category><![CDATA[concern-warning]]></category>

		<category><![CDATA[craig-philips]]></category>

		<category><![CDATA[efforts]]></category>

		<category><![CDATA[exelixis]]></category>

		<category><![CDATA[from-the-colon]]></category>

		<category><![CDATA[major-milestone]]></category>

		<category><![CDATA[million-through]]></category>

		<category><![CDATA[struggling]]></category>

		<category><![CDATA[therapeutics]]></category>

		<category><![CDATA[well-as-its]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/fda-oks-cell-therapeutics-manufacturing-plant</guid>
		<description><![CDATA[ The FDA has approved Cell Therapeutics' facility to manufacture Pixuvri (pixantrone), an experimental cancer drug that is currently]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/fda-oks-cell-therapeutics-manufacturing-plant/feed</wfw:commentRss>
		</item>
		<item>
		<title>Use of social media for health: A common sense approach</title>
		<link>http://pharma-marketer.brollyclient.ca/dtc/use-of-social-media-for-health-a-common-sense-approach</link>
		<comments>http://pharma-marketer.brollyclient.ca/dtc/use-of-social-media-for-health-a-common-sense-approach#comments</comments>
		<pubDate>Mon, 08 Mar 2010 17:04:36 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[DTC]]></category>

		<category><![CDATA[conversation]]></category>

		<category><![CDATA[cymbalta]]></category>

		<category><![CDATA[explode-as-more]]></category>

		<category><![CDATA[money]]></category>

		<category><![CDATA[power]]></category>

		<category><![CDATA[savior]]></category>

		<category><![CDATA[Social Media]]></category>

		<category><![CDATA[traffic]]></category>

		<category><![CDATA[twitter]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/use-of-social-media-for-health-a-common-sense-approach</guid>
		<description><![CDATA[Trust. Before I have a relationship with you I need to trust you and right now consumers/patients don't trust pharma, medical device companies or the FDA. In fact if you're a healthcare consumer right now, and who isn't, you're probably confused as hell about all the recent news around medications and health conditions]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/dtc/use-of-social-media-for-health-a-common-sense-approach/feed</wfw:commentRss>
		</item>
		<item>
		<title>Rapaflo – Rapid Relief</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/rapaflo-%e2%80%93-rapid-relief</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/rapaflo-%e2%80%93-rapid-relief#comments</comments>
		<pubDate>Mon, 08 Mar 2010 17:00:09 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[north america]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[rapid-relief]]></category>

		<category><![CDATA[signs]]></category>

		<category><![CDATA[silodosin]]></category>

		<category><![CDATA[single-page]]></category>

		<category><![CDATA[the-largest]]></category>

		<category><![CDATA[the-signs]]></category>

		<category><![CDATA[usa]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/rapaflo-%e2%80%93-rapid-relief</guid>
		<description><![CDATA[ Rapid Relief Brand name: Rapaflo Generic name/category: Silodosin Company: Watson Country/Market: USA, North America Indication(s)/use: treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) Target: Healthcare Professionals (HCP) Tagline: Ready. Set]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/rapaflo-%e2%80%93-rapid-relief/feed</wfw:commentRss>
		</item>
		<item>
		<title>InterMune stock rise ahead of meeting</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/intermune-stock-rise-ahead-of-meeting</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/intermune-stock-rise-ahead-of-meeting#comments</comments>
		<pubDate>Mon, 08 Mar 2010 16:18:52 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[allergy-drugs]]></category>

		<category><![CDATA[collaborations]]></category>

		<category><![CDATA[drugs]]></category>

		<category><![CDATA[intermune]]></category>

		<category><![CDATA[pirfenidone]]></category>

		<category><![CDATA[struggling]]></category>

		<category><![CDATA[the-clinical]]></category>

		<category><![CDATA[were-braced]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/intermune-stock-rise-ahead-of-meeting</guid>
		<description><![CDATA[ The Pulmonary-Allergy Drugs Advisory Committee will meet tomorrow to discuss InterMune's idiopathic pulmonary fibrosis candidate pirfenidone, a product FDA staffers expressed concern about in briefing documents. FDA reviewers said only one of the company's two key trials showed efficacy, and "the clinical significance of the treatment effect size is uncertain." Despite the agency's concerns, investors who were braced for a more negative analysis sent the company's shares soaring Friday]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/intermune-stock-rise-ahead-of-meeting/feed</wfw:commentRss>
		</item>
		<item>
		<title>Rapaflo – Rapid relief that keeps him going</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/rapaflo-%e2%80%93-rapid-relief-that-keeps-him-going</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/rapaflo-%e2%80%93-rapid-relief-that-keeps-him-going#comments</comments>
		<pubDate>Mon, 08 Mar 2010 16:00:06 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[north america]]></category>

		<category><![CDATA[silodosin]]></category>

		<category><![CDATA[single-page]]></category>

		<category><![CDATA[usa]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/rapaflo-%e2%80%93-rapid-relief-that-keeps-him-going</guid>
		<description><![CDATA[ Rapid relief that keeps him going Brand name: Rapaflo Generic name/category: Silodosin Company: Watson Country/Market: USA, North America Indication(s)/use: treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) Target: Healthcare Professionals (HCP) Tagline: Ready. Set. Go. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/rapaflo-%e2%80%93-rapid-relief-that-keeps-him-going/feed</wfw:commentRss>
		</item>
		<item>
		<title>XenoPort cuts 50% of workforce</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/xenoport-cuts-50-of-workforce</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/xenoport-cuts-50-of-workforce#comments</comments>
		<pubDate>Mon, 08 Mar 2010 15:53:53 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[discovery]]></category>

		<category><![CDATA[drugs]]></category>

		<category><![CDATA[glaxo]]></category>

		<category><![CDATA[horizant]]></category>

		<category><![CDATA[its-late-stage]]></category>

		<category><![CDATA[layoffs]]></category>

		<category><![CDATA[the-clinical]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/xenoport-cuts-50-of-workforce</guid>
		<description><![CDATA[ In a terse announcement released Friday, Santa Clara, CA-based XenoPort said it's cutting 50 percent of its 219-person staff and refocusing its development efforts on its late-stage product candidates. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/xenoport-cuts-50-of-workforce/feed</wfw:commentRss>
		</item>
		<item>
		<title>The biotech spring arrives in Barcelona</title>
		<link>http://pharma-marketer.brollyclient.ca/news-2/the-biotech-spring-arrives-in-barcelona</link>
		<comments>http://pharma-marketer.brollyclient.ca/news-2/the-biotech-spring-arrives-in-barcelona#comments</comments>
		<pubDate>Mon, 08 Mar 2010 15:51:54 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Top News]]></category>

		<category><![CDATA[barcelona]]></category>

		<category><![CDATA[biopharma-giant]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[discovery]]></category>

		<category><![CDATA[drugs]]></category>

		<category><![CDATA[french]]></category>

		<category><![CDATA[gathering-crowd]]></category>

		<category><![CDATA[glaxo]]></category>

		<category><![CDATA[In the Pipeline]]></category>

		<category><![CDATA[isabelle-thizon]]></category>

		<category><![CDATA[its-late-stage]]></category>

		<category><![CDATA[layoffs]]></category>

		<category><![CDATA[palau-pharma]]></category>

		<category><![CDATA[told-the-crowd]]></category>

		<category><![CDATA[vice-president]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/the-biotech-spring-arrives-in-barcelona</guid>
		<description><![CDATA[ BARCELONA -- The theme here at BIO-Europe Spring 2010]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/news-2/the-biotech-spring-arrives-in-barcelona/feed</wfw:commentRss>
		</item>
		<item>
		<title>Not Gonna Make That One</title>
		<link>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/not-gonna-make-that-one</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/not-gonna-make-that-one#comments</comments>
		<pubDate>Mon, 08 Mar 2010 15:25:45 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[In the Pipeline]]></category>

		<category><![CDATA[compound]]></category>

		<category><![CDATA[conference-room]]></category>

		<category><![CDATA[enough-chemists]]></category>

		<category><![CDATA[hundred-million]]></category>

		<category><![CDATA[life in the drug labs]]></category>

		<category><![CDATA[other-compound]]></category>

		<category><![CDATA[raw-naphthalene]]></category>

		<category><![CDATA[someone-shows]]></category>

		<category><![CDATA[think-the-odds]]></category>

		<category><![CDATA[work-at-first]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/not-gonna-make-that-one</guid>
		<description><![CDATA[ A discussion at work the other day got me to thinking: what structures do you medicinal chemists out there just refuse to work on? ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/not-gonna-make-that-one/feed</wfw:commentRss>
		</item>
		<item>
		<title>Transtec – puzzle pieces BE</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/transtec-%e2%80%93-puzzle-pieces-be</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/transtec-%e2%80%93-puzzle-pieces-be#comments</comments>
		<pubDate>Mon, 08 Mar 2010 15:00:22 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[belgium]]></category>

		<category><![CDATA[europe]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[north america]]></category>

		<category><![CDATA[parce-que]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[silodosin]]></category>

		<category><![CDATA[single-page]]></category>

		<category><![CDATA[transtec]]></category>

		<category><![CDATA[usa]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/transtec-%e2%80%93-puzzle-pieces-be</guid>
		<description><![CDATA[ Transtec chez les gens agés : parce que les pièces du puzzle s&#8217;assemblent parfaitement Brand name: Transtec Generic name/category: Buprenorphine transdermal patch Company: Grünenthal Country/Market: Belgium, Europe Indication(s)/use: Moderate to severe cancer-related pain Target: Healthcare Professionals (HCP) Tagline: n/a Medium: Print ad Size/duration: Three quarters of page Publication/Aired: March 2010 To see all of this brand&#8217;s ads on AdPharm, click here Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/transtec-%e2%80%93-puzzle-pieces-be/feed</wfw:commentRss>
		</item>
		<item>
		<title>Azyter - efficace, simple et court</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/azyter-efficace-simple-et-court</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/azyter-efficace-simple-et-court#comments</comments>
		<pubDate>Mon, 08 Mar 2010 12:03:40 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/azyter-efficace-simple-et-court</guid>
		<description><![CDATA[ Click here to see the ad ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/azyter-efficace-simple-et-court/feed</wfw:commentRss>
		</item>
		<item>
		<title>Facebook Can Increase Revenue and Loyalty for healthcare marketing</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/facebook-can-increase-revenue-and-loyalty-for-healthcare-marketing</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/facebook-can-increase-revenue-and-loyalty-for-healthcare-marketing#comments</comments>
		<pubDate>Sun, 07 Mar 2010 22:07:28 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[business]]></category>

		<category><![CDATA[dollars-spent]]></category>

		<category><![CDATA[facebook]]></category>

		<category><![CDATA[hospital marketing]]></category>

		<category><![CDATA[know-people]]></category>

		<category><![CDATA[rest]]></category>

		<category><![CDATA[social marketing]]></category>

		<category><![CDATA[store-visits]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/facebook-can-increase-revenue-and-loyalty-for-healthcare-marketing</guid>
		<description><![CDATA[ A recent study found that Facebook fan pages can increase store visits, dollars spent and customer loyalty. Facebook now has over 400 million accounts with 50 million of those created since last fall. We know people are on Facebook]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/facebook-can-increase-revenue-and-loyalty-for-healthcare-marketing/feed</wfw:commentRss>
		</item>
		<item>
		<title>Pharma Companies to Employ Behavioral Targeting with Caution</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/pharma-companies-to-employ-behavioral-targeting-with-caution</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/pharma-companies-to-employ-behavioral-targeting-with-caution#comments</comments>
		<pubDate>Sun, 07 Mar 2010 15:19:52 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[ad-ology]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[behavioral-targeting]]></category>

		<category><![CDATA[interactive]]></category>

		<category><![CDATA[internet]]></category>

		<category><![CDATA[marketing]]></category>

		<category><![CDATA[online]]></category>

		<category><![CDATA[seatch advertising]]></category>

		<category><![CDATA[social marketing]]></category>

		<category><![CDATA[Social Media]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/pharma-companies-to-employ-behavioral-targeting-with-caution</guid>
		<description><![CDATA[ Story on Ad-ology by marketingforecast.com ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/pharma-companies-to-employ-behavioral-targeting-with-caution/feed</wfw:commentRss>
		</item>
		<item>
		<title>Viagra - party blower</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/viagra-party-blower</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/viagra-party-blower#comments</comments>
		<pubDate>Sun, 07 Mar 2010 14:41:45 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/viagra-party-blower</guid>
		<description><![CDATA[ Click here to see the ad ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/viagra-party-blower/feed</wfw:commentRss>
		</item>
		<item>
		<title>Ligue-cancer.net - Ã©quipe</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ligue-cancernet-a%c2%a9quipe</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ligue-cancernet-a%c2%a9quipe#comments</comments>
		<pubDate>Sun, 07 Mar 2010 14:41:44 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/ligue-cancernet-a%c2%a9quipe</guid>
		<description><![CDATA[ Click here to see the ad ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ligue-cancernet-a%c2%a9quipe/feed</wfw:commentRss>
		</item>
		<item>
		<title>Ordre des Pharmaciens du Québec help clear up the health system in Quebec</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ordre-des-pharmaciens-du-quebec-help-clear-up-the-health-system-in-quebec</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ordre-des-pharmaciens-du-quebec-help-clear-up-the-health-system-in-quebec#comments</comments>
		<pubDate>Sun, 07 Mar 2010 13:55:43 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[ad-ology]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[allowing-quebec]]></category>

		<category><![CDATA[behavioral-targeting]]></category>

		<category><![CDATA[change-patients]]></category>

		<category><![CDATA[importance]]></category>

		<category><![CDATA[marketing]]></category>

		<category><![CDATA[pharmacist]]></category>

		<category><![CDATA[phone]]></category>

		<category><![CDATA[population]]></category>

		<category><![CDATA[social marketing]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/ordre-des-pharmaciens-du-quebec-help-clear-up-the-health-system-in-quebec</guid>
		<description><![CDATA[ An awareness campaign called &#8220;Un pharmacien au bout du fil&#8221; ( A pharmacist at the other end of the phone ) organized by L&#8217; Ordre des Pharmaciens du Québec is taking place this weekend. Although this effort is ending today, we thought this marketing effort was worth mentioning for it&#8217;s underlying premise. Pharmacists respond to questions from Quebecers for free, Saturday and Sunday (March 6 and 7) between 9am and 16h at 514-788-3398 (Montreal) and 1-877-957-2683 (for the rest of the province)]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/ordre-des-pharmaciens-du-quebec-help-clear-up-the-health-system-in-quebec/feed</wfw:commentRss>
		</item>
		<item>
		<title>INPES – flying bacteria</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/inpes-%e2%80%93-flying-bacteria</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/inpes-%e2%80%93-flying-bacteria#comments</comments>
		<pubDate>Sat, 06 Mar 2010 15:00:59 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[consumers]]></category>

		<category><![CDATA[DTC]]></category>

		<category><![CDATA[europe]]></category>

		<category><![CDATA[flying-bacteria]]></category>

		<category><![CDATA[france]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[man-sneezes]]></category>

		<category><![CDATA[more-numbers]]></category>

		<category><![CDATA[mouth]]></category>

		<category><![CDATA[the-largest]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/inpes-%e2%80%93-flying-bacteria</guid>
		<description><![CDATA[ Work colleagues are having a breakfast working session. Numbers are floating around them. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/inpes-%e2%80%93-flying-bacteria/feed</wfw:commentRss>
		</item>
		<item>
		<title>Transtec - puzzle pieces BE</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/transtec-puzzle-pieces-be</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/transtec-puzzle-pieces-be#comments</comments>
		<pubDate>Sat, 06 Mar 2010 12:44:05 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/transtec-puzzle-pieces-be</guid>
		<description><![CDATA[ Click here to see the ad ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/transtec-puzzle-pieces-be/feed</wfw:commentRss>
		</item>
		<item>
		<title>Rapaflo - Rapid Relief US</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/rapaflo-rapid-relief-us</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/rapaflo-rapid-relief-us#comments</comments>
		<pubDate>Sat, 06 Mar 2010 12:00:03 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/rapaflo-rapid-relief-us</guid>
		<description><![CDATA[ Click here to see the ad ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/rapaflo-rapid-relief-us/feed</wfw:commentRss>
		</item>
		<item>
		<title>Merck/Schering-Plough People?</title>
		<link>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/merckschering-plough-people</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/merckschering-plough-people#comments</comments>
		<pubDate>Fri, 05 Mar 2010 22:14:59 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[In the Pipeline]]></category>

		<category><![CDATA[business and markets]]></category>

		<category><![CDATA[cbs]]></category>

		<category><![CDATA[direct-knowledge]]></category>

		<category><![CDATA[girard]]></category>

		<category><![CDATA[how-people]]></category>

		<category><![CDATA[interactive]]></category>

		<category><![CDATA[merger]]></category>

		<category><![CDATA[she-gets]]></category>

		<category><![CDATA[story-on-how]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/merckschering-plough-people</guid>
		<description><![CDATA[ Kim Girard, a reporter from CBS Interactive is doing a story on how people are coping with the merger - if you'd like to speak with her, she's at (de-spammified): kim.berg30-at-gmail.com. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/merckschering-plough-people/feed</wfw:commentRss>
		</item>
		<item>
		<title>Friday Book Recommendation</title>
		<link>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/friday-book-recommendation</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/friday-book-recommendation#comments</comments>
		<pubDate>Fri, 05 Mar 2010 19:45:54 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[In the Pipeline]]></category>

		<category><![CDATA[book]]></category>

		<category><![CDATA[boston]]></category>

		<category><![CDATA[business and markets]]></category>

		<category><![CDATA[cbs]]></category>

		<category><![CDATA[fermi-paradox]]></category>

		<category><![CDATA[girard]]></category>

		<category><![CDATA[math]]></category>

		<category><![CDATA[merger]]></category>

		<category><![CDATA[she-gets]]></category>

		<category><![CDATA[story-on-how]]></category>

		<category><![CDATA[telescope]]></category>

		<category><![CDATA[weather]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/friday-book-recommendation</guid>
		<description><![CDATA[ Here's another outside the field - in fact, it's outside of a lot of people's fields. Where Is Everybody? ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/friday-book-recommendation/feed</wfw:commentRss>
		</item>
		<item>
		<title>Twelve and One Half Per Cent</title>
		<link>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/twelve-and-one-half-per-cent</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/twelve-and-one-half-per-cent#comments</comments>
		<pubDate>Fri, 05 Mar 2010 19:41:20 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[In the Pipeline]]></category>

		<category><![CDATA[base]]></category>

		<category><![CDATA[been-granted]]></category>

		<category><![CDATA[business and markets]]></category>

		<category><![CDATA[ceo]]></category>

		<category><![CDATA[his-base]]></category>

		<category><![CDATA[kindler]]></category>

		<category><![CDATA[pfizer]]></category>

		<category><![CDATA[will-note]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/twelve-and-one-half-per-cent</guid>
		<description><![CDATA[ I will note here, with no additional comment whatsoever, that Jeff Kindler, Pfizer's CEO, has just been granted a raise in his base salary of 12.5%. Details at Pharmalot . ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/twelve-and-one-half-per-cent/feed</wfw:commentRss>
		</item>
		<item>
		<title>Pharma Should Leave Unmoderated SM Discussions to 3rd Parties</title>
		<link>http://pharma-marketer.brollyclient.ca/traditional-strategies/pharma-should-leave-unmoderated-sm-discussions-to-3rd-parties</link>
		<comments>http://pharma-marketer.brollyclient.ca/traditional-strategies/pharma-should-leave-unmoderated-sm-discussions-to-3rd-parties#comments</comments>
		<pubDate>Fri, 05 Mar 2010 16:48:01 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Traditional Strategies]]></category>

		<category><![CDATA[complaints]]></category>

		<category><![CDATA[conversation]]></category>

		<category><![CDATA[disfigurment]]></category>

		<category><![CDATA[imagine-the-day]]></category>

		<category><![CDATA[internet]]></category>

		<category><![CDATA[marketing]]></category>

		<category><![CDATA[motivations]]></category>

		<category><![CDATA[Regulatory]]></category>

		<category><![CDATA[total]]></category>

		<category><![CDATA[twittersphere]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/pharma-should-leave-unmoderated-sm-discussions-to-3rd-parties</guid>
		<description><![CDATA[ In comments addressed to the FDA, many drug companies and ad hoc industry groups are suggesting ways drug companies can legally "engage" with patients, physicians, and consumers in online social media discussions (see, for example, " A Pharma 'Social Media Working Group' Submits Comments to FDA "). The hope is that new FDA guidelines (or regulations) will help them do that. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/traditional-strategies/pharma-should-leave-unmoderated-sm-discussions-to-3rd-parties/feed</wfw:commentRss>
		</item>
		<item>
		<title>Premarin – proven effective</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/premarin-%e2%80%93-proven-effective</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/premarin-%e2%80%93-proven-effective#comments</comments>
		<pubDate>Fri, 05 Mar 2010 15:50:13 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[advertising]]></category>

		<category><![CDATA[conjugated]]></category>

		<category><![CDATA[even-at-low]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[north america]]></category>

		<category><![CDATA[the-largest]]></category>

		<category><![CDATA[the-treatment]]></category>

		<category><![CDATA[treatment]]></category>

		<category><![CDATA[usa]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/premarin-%e2%80%93-proven-effective</guid>
		<description><![CDATA[ Less than you think Brand name: Premarin Generic name/category: Conjugated estrogens, vaginal cream Company: Pfizer Country/Market: USA, North America Indication(s)/use: atrophic vaginitis and kraurosis vulvae and the treatment of moderate to severe dyspareunia. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/premarin-%e2%80%93-proven-effective/feed</wfw:commentRss>
		</item>
		<item>
		<title>Mirena – gives her control</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/mirena-%e2%80%93-gives-her-control</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/mirena-%e2%80%93-gives-her-control#comments</comments>
		<pubDate>Fri, 05 Mar 2010 15:49:26 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[contraceptive]]></category>

		<category><![CDATA[control-over]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[usa]]></category>

		<category><![CDATA[uterine-system]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/mirena-%e2%80%93-gives-her-control</guid>
		<description><![CDATA[ Mirena gives her control over her birth control Brand name: Mirena Generic name/category: levonorgestrel-releasing intrauterine system, IntraUterine System (IUS), contraceptive Company: Bayer Healthcare Pharmaceuticals Country/Market: USA, North America Indication(s)/use: Contraceptive, birth control Target: Healthcare Professionals (HCP) Tagline: Keep life simple. Medium: Print ad Size/duration single-page Publication/Aired: March 2010 To see all of this brand&#8217;s ads, click here Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/mirena-%e2%80%93-gives-her-control/feed</wfw:commentRss>
		</item>
		<item>
		<title>Amgen – There’s a key signal that can’t be ignored</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/amgen-%e2%80%93-there%e2%80%99s-a-key-signal-that-can%e2%80%99t-be-ignored</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/amgen-%e2%80%93-there%e2%80%99s-a-key-signal-that-can%e2%80%99t-be-ignored#comments</comments>
		<pubDate>Fri, 05 Mar 2010 15:48:38 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[bone-disease]]></category>

		<category><![CDATA[key-signal]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[north america]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[two-thirds]]></category>

		<category><![CDATA[usa]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/amgen-%e2%80%93-there%e2%80%99s-a-key-signal-that-can%e2%80%99t-be-ignored</guid>
		<description><![CDATA[ In prostate cancer-induced bone disease, there&#8217;s a key signal that can&#8217;t be ignored. Generic name/category: Rank ligand, TNF-related Company: Amgen Country/Market: USA, North America Indication(s)/use: prostate cancer-induced bone disease Target: Healthcare Professionals (HCP) Tagline: n/a Medium: print ad Size/duration: Two-thirds of page Publication/Aired: March 2010 To see all of this brand&#8217;s ads on AdPharm, click here Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/amgen-%e2%80%93-there%e2%80%99s-a-key-signal-that-can%e2%80%99t-be-ignored/feed</wfw:commentRss>
		</item>
		<item>
		<title>Testim 1% – recharge</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/testim-1-%e2%80%93-recharge</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/testim-1-%e2%80%93-recharge#comments</comments>
		<pubDate>Fri, 05 Mar 2010 15:47:36 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[adult-males]]></category>

		<category><![CDATA[bone-disease]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[north america]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[recharge]]></category>

		<category><![CDATA[testosterone]]></category>

		<category><![CDATA[the-largest]]></category>

		<category><![CDATA[two-thirds]]></category>

		<category><![CDATA[usa]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/testim-1-%e2%80%93-recharge</guid>
		<description><![CDATA[ Recharge Brand name: Testim Generic name/category: Testosterone Gel Company: Auxilium Pharmaceuticals Country/Market: USA, North America Indication(s)/use: hypogonadism, replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone Target: Healthcare Professionals (HCP) Tagline: Recharge Medium: Print ad Size/duration: Single-page Publication/Aired: March 2010 To see all of this brand&#8217;s ads on AdPharm, click here Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/testim-1-%e2%80%93-recharge/feed</wfw:commentRss>
		</item>
		<item>
		<title>Lovaza – Too much fat in your blood</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/lovaza-%e2%80%93-too-much-fat-in-your-blood</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/lovaza-%e2%80%93-too-much-fat-in-your-blood#comments</comments>
		<pubDate>Fri, 05 Mar 2010 15:47:02 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<category><![CDATA[adpharm gallery]]></category>

		<category><![CDATA[adult-males]]></category>

		<category><![CDATA[largest]]></category>

		<category><![CDATA[medical-term]]></category>

		<category><![CDATA[north]]></category>

		<category><![CDATA[north america]]></category>

		<category><![CDATA[Print]]></category>

		<category><![CDATA[testosterone]]></category>

		<category><![CDATA[usa]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/lovaza-%e2%80%93-too-much-fat-in-your-blood</guid>
		<description><![CDATA[ Very high triglycerides is a medical term for something serious: Too much fat in your blood. Brand name: Lovaza Generic name/category: Omega-3-acid ethyl esters Company: GlaxoSmithKline Country/Market: USA, North America Indication(s)/use: high triglycerides Target: Consumers (DTC) Tagline: n/a Medium: Print ad Size/duration: Single-page Publication/Aired: January 2010 To see all of this brand&#8217;s ads on AdPharm, click here Click here for the full-sized ad and details in the AdPharm gallery Subscription-based AdPharm gallery is the largest keyword searchable online pharmaceutical advertising gallery. ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/lovaza-%e2%80%93-too-much-fat-in-your-blood/feed</wfw:commentRss>
		</item>
		<item>
		<title>The Bleeding Has Stopped!</title>
		<link>http://pharma-marketer.brollyclient.ca/dtc/the-bleeding-has-stopped</link>
		<comments>http://pharma-marketer.brollyclient.ca/dtc/the-bleeding-has-stopped#comments</comments>
		<pubDate>Fri, 05 Mar 2010 15:20:43 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[DTC]]></category>

		<category><![CDATA[congress]]></category>

		<category><![CDATA[foreseeable]]></category>

		<category><![CDATA[industries]]></category>

		<category><![CDATA[internet]]></category>

		<category><![CDATA[lifeblood]]></category>

		<category><![CDATA[livelihoods]]></category>

		<category><![CDATA[risk-disclosure]]></category>

		<category><![CDATA[strong-presence]]></category>

		<category><![CDATA[television]]></category>

		<category><![CDATA[warning letters]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/the-bleeding-has-stopped</guid>
		<description><![CDATA[ Despite some critics saying DTC was heading to a permanent downturn, after a serious first half 2009 decline, the second half was so positive the year ended up. Spending ended up 2% according to data from Kantar Media. Usually I do not get excited about 2% increases]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/dtc/the-bleeding-has-stopped/feed</wfw:commentRss>
		</item>
		<item>
		<title>Your Own Personal Bacteria</title>
		<link>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/your-own-personal-bacteria</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/your-own-personal-bacteria#comments</comments>
		<pubDate>Fri, 05 Mar 2010 14:53:52 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[In the Pipeline]]></category>

		<category><![CDATA[bacteria]]></category>

		<category><![CDATA[biological news]]></category>

		<category><![CDATA[european]]></category>

		<category><![CDATA[human]]></category>

		<category><![CDATA[knowledge]]></category>

		<category><![CDATA[paper]]></category>

		<category><![CDATA[planets]]></category>

		<category><![CDATA[press]]></category>

		<category><![CDATA[study]]></category>

		<category><![CDATA[surely-realizes]]></category>

		<category><![CDATA[work]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/your-own-personal-bacteria</guid>
		<description><![CDATA[ There's a report in Nature on the bacteria found in the human gut that's getting a lot of press today (especially for a paper about, well, bacteria in the human gut). A team at the Beijing Genomics Institute, with many collaborators, has done a large shotgun sequencing effort on gut flora and identified perhaps one thousand different species. I can well believe it]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/in-the-pipeline/your-own-personal-bacteria/feed</wfw:commentRss>
		</item>
		<item>
		<title>Amgen - rank ligand US</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/amgen-rank-ligand-us</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/amgen-rank-ligand-us#comments</comments>
		<pubDate>Fri, 05 Mar 2010 14:05:34 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/amgen-rank-ligand-us</guid>
		<description><![CDATA[ Click here to see the ad ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/amgen-rank-ligand-us/feed</wfw:commentRss>
		</item>
		<item>
		<title>SensiGene - prenatal diagnostics US</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/sensigene-prenatal-diagnostics-us</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/sensigene-prenatal-diagnostics-us#comments</comments>
		<pubDate>Fri, 05 Mar 2010 13:59:58 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/sensigene-prenatal-diagnostics-us</guid>
		<description><![CDATA[ Click here to see the ad ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/sensigene-prenatal-diagnostics-us/feed</wfw:commentRss>
		</item>
		<item>
		<title>Mirena - control US</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/mirena-control-us</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/mirena-control-us#comments</comments>
		<pubDate>Fri, 05 Mar 2010 13:59:57 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/mirena-control-us</guid>
		<description><![CDATA[ Click here to see the ad ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/mirena-control-us/feed</wfw:commentRss>
		</item>
		<item>
		<title>Premarin - proven effective US</title>
		<link>http://pharma-marketer.brollyclient.ca/more/pharma-ads/premarin-proven-effective-us</link>
		<comments>http://pharma-marketer.brollyclient.ca/more/pharma-ads/premarin-proven-effective-us#comments</comments>
		<pubDate>Fri, 05 Mar 2010 13:59:55 +0000</pubDate>
		<dc:creator>Pharma Marketer</dc:creator>
		
		<category><![CDATA[Pharma Ads]]></category>

		<guid isPermaLink="false">http://pharma-marketer.brollyclient.ca/news-2/premarin-proven-effective-us</guid>
		<description><![CDATA[ Click here to see the ad ]]></description>
			<content:encoded><![CDATA[]]></content:encoded>
			<wfw:commentRss>http://pharma-marketer.brollyclient.ca/more/pharma-ads/premarin-proven-effective-us/feed</wfw:commentRss>
		</item>
	</channel>
</rss>
<!-- WP Super Cache is installed but broken. The path to wp-cache-phase1.php in wp-content/advanced-cache.php must be fixed! -->